[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"I.T.S. GmbH\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":245},{"warningLetters":4,"total":244},[5,31,53,75,97,115,132,151,168,191,207,223],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},2097,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2023-05-23T04:00:00Z\">05\u002F23\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-05-19T04:00:00Z\">05\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fits-gmbh-657885-05192023\">I.T.S. GmbH\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FManufacture\u002FPacking\u002FStorage\u002FInstallation\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mag. Wolfgang Auf\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>I.T.S. GmbH\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Autal 28 Lassnithohe\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>8301\u003C\u002Fspan> \u003Cspan>Steiermark\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Austria\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 19, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Wolfgang Auf:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Lassnithohe, Steiermark, 8301 on January 16, 2023, through January 19, 2023, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures bone fixation devices and other class II devices. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received a response from Ing. Florian Grill dated February 7, 2023, and March 20, 2023, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, per 21 CFR 820.100(a).\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cp>a) Your firm's procedure titled CAPA System (Corrective and Preventive Actions), ITS PB-7.6-2 Edition 9 Effective June 17, 2021, does not include adequate requirements to ensure investigations of the cause of nonconformities, or adequate requirements to ensure the implementing and recording changes in methods and procedures needed to correct and prevent identified quality problems and corrective and preventive actions. Specifically, section 2.3 of the procedure titled Investigation and Analysis states: \"\u003Cem>The event will be investigated together with the members of the department, in which the non-conformity was detected. The results of the investigation will be analyzed and stated in the CAPA form. The cause will be defined, and the corrective action created\u003C\u002Fem>.\" This section does not define methods of investigation which would provide employees a means to investigate recurring nonconformities across all possible processes\u002Fareas where the nonconformities may affect product. In addition, your procedure does not include adequate requirements to ensure the information related to quality problems or nonconforming products is adequately disseminated to persons responsible for assuring the quality of the product and prevention of such problems.\u003C\u002Fp>\n\n\u003Cp>b) CAPA form, Form F-8.5.1_CAPA_Formblatt_REV06_015_2022, was initiated on September 7, 2022, as a result of three similar errors found during Incoming QC (IQC) inspections of deliveries from the supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> due to dimensional deviation of the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>A Supplier Corrective Action Request, SCAR 11_679\u002F2022, was sent to \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>requesting an investigation and corrective actions to fix the deviations in dimensions. However, your firm did not include documentation to demonstrate adequate investigation of this quality issue, implementation of corrective actions and distribution of this quality issue to persons required to ensure the quality of the products.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated February 7, 2023, and March 20, 2023, and conclude that your firm's response to this observation is inadequate.\u003C\u002Fp>\n\n\u003Cp>You provided a revised version of your CAPA procedure, CAPA System (Corrective and Preventative Actions) PB-7.6-2, Revision 10, effective date 01\u002F27\u002F2023. Sections 2.2 was revised to include causes of nonconformities that may trigger an investigation to include external complaint, internal complaint, self-identified potential for improvement, audits\u002Finspection, recall and supplier failure. Your procedure outlined steps for when to open a CAPA or NCR (Nonconformance Report). Procedural step for creation and processing of a CAPA report is outlined in section 2.2 and 2.2.1 of this revised procedure. Sections 2.3 and 2.3.1 were revised to outline conducting of a root cause analysis (by means of Ishikawa, 5-why or the like) and potential root causes defined, such as events caused by employees, equipment, document failure, or other causes. Your revised procedure explicitly states that a CAPA can only be closed after completion of effectiveness check and that this is to be documented. Requirement for training of necessary personnel is stated in section 2.4 of your revised procedure. Your also updated CAPA Form, F_8.5.1_CAPA_Formblatt_Rev07 to address the deficiencies noted in observation, including providing clear method for documentation of investigation and implementation of actions. Your revised SOP references form F-8.5.1_CAPA_Formblatt in several sections (as needed to initiate the CAPA process, and document investigation, event classification, corrective and preventive action, and effectiveness checks).\u003C\u002Fp>\n\n\u003Cp>Your revised procedure is accompanied by documentation (i.e., signatures on Form F-6.2.2.2) of training to four \"management staff'. However, you have not provided evidence of training of additional personnel directly responsible for assuring the quality of product or the prevention of product quality problems. Your firm should provide documentation of training of all relevant personnel responsible for assuring the quality of products. Also, confirm that you have conducted review of prior CAPA(s) per the revised procedure and taken necessary actions to ensure that the revised procedure is adequately implemented, including CAPA investigations are adequately documented. Your firm's future response should provide detailed activities conducted and status of those activities to ensure compliance with the revised CAPA procedure.\u003C\u002Fp>\n\n\u003Cp>2. Failure to maintain adequate device history records (DHR's), as required by 21 CFR 820.184. For example: Your firm did not maintain the primary identification label and labeling used for each production unit in your DHR as required by 21 CFR 820.184 (e). During walkthrough of your facility, the FDA investigator observed that your firm \"\u003Cem>do check the accuracy of the label prior to initiating labeling operations\u003C\u002Fem>\". However, the FDA investigator also noted that \"\u003Cem>this is not documented in the DHR\u003C\u002Fem>\" . This deficiency was discussed with your firm management at the end of the inspection.\u003C\u002Fp>\n\n\u003Cp>Your firm's response dated February 7, 2023, and March 21, 2023, did not address this deficiency as it was discussed with your firm's management at the close of the Inspection and not cited as an observation on the FDA-483. Your firm's future response should address what systemic measures were taken to address this deficiency and provide evidence of implementation of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm's implantable orthopedic devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, your firm presented the following documents as your written MDR procedure.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Document titled \"Feedback Handling\", VA-8.2.1, Revision 14, dated September 19,2022\u003C\u002Fli>\n\t\u003Cli>Document titled \"MDR (Medical Device Reporting)\", PD-8.5, Revision 5, dated May 17, 2022\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cp>1) The procedure does not establish internal systems that provide for timely and effective\u003Cbr>\nidentification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\u003C\u002Fp>\n\n\u003Cp>a. The procedure omits the definitions from 21 CFR Part 803.3 for the terms \"become aware\" and \"caused or contributed\", and the definition for the term \"reasonable suggests\", found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\n\n\u003Cp>b. The procedure does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fp>\n\n\u003Cp>2) The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\u003C\u002Fp>\n\n\u003Cp>a. Documentation of adverse event related information maintained as MDR event files.\u003C\u002Fp>\n\n\u003Cp>b. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated February 7,2023 and conclude that it is not adequate. The response includes your revised procedure titled \"MDR (Medical Device Reporting)\", PD-8.5, Revision 6, dated 2\u002F2\u002F2023, and staff training records. However, after reviewing the referenced document, the following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cp>3) The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). However, the procedure omits the definition from 21 CFR Part 803.3 for the term \"caused or contributed\", and the definition for the term \"reasonably suggests\", found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\n\n\u003Cp>4) The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated March 20, 2023, and conclude that it is not adequate. The response includes a revised Complaint Form (Form No. F-8.2.1-1) titled \"DATA Acquisition I.T.S Products\", Revision 04, dated February 1,2023, and staff training records. However, upon collectively reviewing your firm's MDR procedure, Revision 6, dated February 2,2023, we conclude that the written MDR procedure lacks definitions of the terms used for the reportability determination outlined above. Please provide your revised procedure incorporating the missing procedural requirements outlined above. Also, confirm that you have retrospectively reviewed relevant MDRs to ensure appropriate actions are taken per the revised procedure. In your future response, please provide detailed activities conducted and status of those activities to ensure compliance with the revised MDR procedure.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. \u003Cstrong>Refer to CMS case #657885 when replying\u003C\u002Fstrong>. If you have any questions about the contents of this letter, please contact: Shumaya Ali, Assistant Director, Stereotaxic, Bone Growth Stimulator, and Fracture Fixation Devices Team at 301-796-2356.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Raquel Peat, Ph.D., M.P.H., USPHS\u003Cbr>\nDirector\u003Cbr>\nOHT 6: Office of Orthopedic Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nJennifer Hadfield\u003Cbr>\nQserve Group US Inc\u003Cbr>\n350 S Main Street, Suite 309\u003Cbr>\nDoylestown, PA 18907\u003Cbr>\nTel# 215-600-3103\u003Cbr>\nEmail: Jennifer.Hadfield@Qservegroup.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMag. Wolfgang Auf\n\nRecipient Title\n\nChief Executive Officer\n\nI.T.S. GmbH\n\nAutal 28 Lassnithohe\n\n8301 Steiermark\n\nAustria\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nMay 19, 2023\n\nWARNING LETTER\n\nDear Mr. Wolfgang Auf:\n\nDuring an inspection of your firm located in Lassnithohe, Steiermark, 8301 on January 16, 2023, through January 19, 2023, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures bone fixation devices and other class II devices. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received a response from Ing. Florian Grill dated February 7, 2023, and March 20, 2023, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, per 21 CFR 820.100(a).\n\nFor example:\n\na) Your firm's procedure titled CAPA System (Corrective and Preventive Actions), ITS PB-7.6-2 Edition 9 Effective June 17, 2021, does not include adequate requirements to ensure investigations of the cause of nonconformities, or adequate requirements to ensure the implementing and recording changes in methods and procedures needed to correct and prevent identified quality problems and corrective and preventive actions. Specifically, section 2.3 of the procedure titled Investigation and Analysis states: \"The event will be investigated together with the members of the department, in which the non-conformity was detected. The results of the investigation will be analyzed and stated in the CAPA form. The cause will be defined, and the corrective action created.\" This section does not define methods of investigation which would provide employees a means to investigate recurring nonconformities across all possible processes\u002Fareas where the nonconformities may affect product. In addition, your procedure does not include adequate requirements to ensure the information related to quality problems or nonconforming products is adequately disseminated to persons responsible for assuring the quality of the product and prevention of such problems.\n\nb) CAPA form, Form F-8.5.1_CAPA_Formblatt_REV06_015_2022, was initiated on September 7, 2022, as a result of three similar errors found during Incoming QC (IQC) inspections of deliveries from the supplier (b)(4) due to dimensional deviation of the (b)(4) A Supplier Corrective Action Request, SCAR 11_679\u002F2022, was sent to (b)(4) requesting an investigation and corrective actions to fix the deviations in dimensions. However, your firm did not include documentation to demonstrate adequate investigation of this quality issue, implementation of corrective actions and distribution of this quality issue to persons required to ensure the quality of the products.\n\nWe reviewed your firm's response dated February 7, 2023, and March 20, 2023, and conclude that your firm's response to this observation is inadequate.\n\nYou provided a revised version of your CAPA procedure, CAPA System (Corrective and Preventative Actions) PB-7.6-2, Revision 10, effective date 01\u002F27\u002F2023. Sections 2.2 was revised to include causes of nonconformities that may trigger an investigation to include external complaint, internal complaint, self-identified potential for improvement, audits\u002Finspection, recall and supplier failure. Your procedure outlined steps for when to open a CAPA or NCR (Nonconformance Report). Procedural step for creation and processing of a CAPA report is outlined in section 2.2 and 2.2.1 of this revised procedure. Sections 2.3 and 2.3.1 were revised to outline conducting of a root cause analysis (by means of Ishikawa, 5-why or the like) and potential root causes defined, such as events caused by employees, equipment, document failure, or other causes. Your revised procedure explicitly states that a CAPA can only be closed after completion of effectiveness check and that this is to be documented. Requirement for training of necessary personnel is stated in section 2.4 of your revised procedure. Your also updated CAPA Form, F_8.5.1_CAPA_Formblatt_Rev07 to address the deficiencies noted in observation, including providing clear method for documentation of investigation and implementation of actions. Your revised SOP references form F-8.5.1_CAPA_Formblatt in several sections (as needed to initiate the CAPA process, and document investigation, event classification, corrective and preventive action, and effectiveness checks).\n\nYour revised procedure is accompanied by documentation (i.e., signatures on Form F-6.2.2.2) of training to four \"management staff'. However, you have not provided evidence of training of additional personnel directly responsible for assuring the quality of product or the prevention of product quality problems. Your firm should provide documentation of training of all relevant personnel responsible for assuring the quality of products. Also, confirm that you have conducted review of prior CAPA(s) per the revised procedure and taken necessary actions to ensure that the revised procedure is adequately implemented, including CAPA investigations are adequately documented. Your firm's future response should provide detailed activities conducted and status of those activities to ensure compliance with the revised CAPA procedure.\n\n2. Failure to maintain adequate device history records (DHR's), as required by 21 CFR 820.184. For example: Your firm did not maintain the primary identification label and labeling used for each production unit in your DHR as required by 21 CFR 820.184 (e). During walkthrough of your facility, the FDA investigator observed that your firm \"do check the accuracy of the label prior to initiating labeling operations\". However, the FDA investigator also noted that \"this is not documented in the DHR\" . This deficiency was discussed with your firm management at the end of the inspection.\n\nYour firm's response dated February 7, 2023, and March 21, 2023, did not address this deficiency as it was discussed with your firm's management at the close of the Inspection and not cited as an observation on the FDA-483. Your firm's future response should address what systemic measures were taken to address this deficiency and provide evidence of implementation of your corrective actions.\n\nOur inspection also revealed that your firm's implantable orthopedic devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\n3. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, your firm presented the following documents as your written MDR procedure.\n\nDocument titled \"Feedback Handling\", VA-8.2.1, Revision 14, dated September 19,2022\n\nDocument titled \"MDR (Medical Device Reporting)\", PD-8.5, Revision 5, dated May 17, 2022\n\nAfter reviewing the procedure, the following deficiencies were noted:\n\n1) The procedure does not establish internal systems that provide for timely and effective\n\nidentification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\n\na. The procedure omits the definitions from 21 CFR Part 803.3 for the terms \"become aware\" and \"caused or contributed\", and the definition for the term \"reasonable suggests\", found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nb. The procedure does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\n\n2) The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\n\na. Documentation of adverse event related information maintained as MDR event files.\n\nb. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\n\nWe reviewed your firm's response dated February 7,2023 and conclude that it is not adequate. The response includes your revised procedure titled \"MDR (Medical Device Reporting)\", PD-8.5, Revision 6, dated 2\u002F2\u002F2023, and staff training records. However, after reviewing the referenced document, the following deficiencies were noted:\n\n3) The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). However, the procedure omits the definition from 21 CFR Part 803.3 for the term \"caused or contributed\", and the definition for the term \"reasonably suggests\", found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\n4) The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\n\nWe reviewed your firm's response dated March 20, 2023, and conclude that it is not adequate. The response includes a revised Complaint Form (Form No. F-8.2.1-1) titled \"DATA Acquisition I.T.S Products\", Revision 04, dated February 1,2023, and staff training records. However, upon collectively reviewing your firm's MDR procedure, Revision 6, dated February 2,2023, we conclude that the written MDR procedure lacks definitions of the terms used for the reportability determination outlined above. Please provide your revised procedure incorporating the missing procedural requirements outlined above. Also, confirm that you have retrospectively reviewed relevant MDRs to ensure appropriate actions are taken per the revised procedure. In your future response, please provide detailed activities conducted and status of those activities to ensure compliance with the revised MDR procedure.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm's response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #657885 when replying. If you have any questions about the contents of this letter, please contact: Shumaya Ali, Assistant Director, Stereotaxic, Bone Growth Stimulator, and Fracture Fixation Devices Team at 301-796-2356.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Raquel Peat, Ph.D., M.P.H., USPHS\n\nDirector\n\nOHT 6: Office of Orthopedic Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nJennifer Hadfield\n\nQserve Group US Inc\n\n350 S Main Street, Suite 309\n\nDoylestown, PA 18907\n\nTel# 215-600-3103\n\nEmail: Jennifer.Hadfield@Qservegroup.com","I.T.S. GmbH","its-gmbh-657885-05192023","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fits-gmbh-657885-05192023","2026-10-26T08:09:01.639697+00:00","Warning Letter","Issued","2023-05-23","657885","Medical Devices","Mag. Wolfgang Auf","2026-08-20T01:06:24.458+00:00","VIA UNITED PARCEL SERVICE","2023-05-19",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},293,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-28T05:00:00Z\">11\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffathers-table-llc-706334-11282025\">The Father&#039;s Table, LLC\u003C\u002Fa>","Human Foods Program","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated\u002FL. monocytogenes","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC DELIVERY\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jeffery B. Liddy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>The Father's Table, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2301 E Lake Mary Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sanford\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32773-7143\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 28, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #706334\u003C\u002Fp>\u003Cp>Dear Mr. Liddy:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your food manufacturing facility, The Father’s Table, LLC, located at 2301 E Lake Mary Blvd, Sanford, FL 32773, from January 13, 2025, through February 13, 2025. Your firm manufactures ready-to-eat (RTE) cheesecakes and cake roll products.\u003C\u002Fp>\u003Cp>During our inspection, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventative Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Additionally, FDA collected environmental samples (i.e., swabs) from various areas in your processing facility. FDA laboratory analyses of the environmental swabs found the presence of \u003Cem>Listeria monocytogenes\u003C\u002Fem> (\u003Cem>L. monocytogenes\u003C\u002Fem>), a human pathogen, in your facility.\u003C\u002Fp>\u003Cp>Based on FDA’s inspectional findings and analytical results revealing \u003Cem>L. monocytogenes\u003C\u002Fem> in your production environment, we have determined that your RTE food products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls’ provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of 21 CFR Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP &amp; PC rule through links in FDA’s home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations, listing deviations found at your facility. We received your firm’s responses to the FDA-483 on March 14, 2025, March 20, 2025, and April 11, 2025, describing corrective actions taken by your firm. After reviewing the inspectional findings and your responses, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility. We discuss your response below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Hazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C):\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. You did not implement preventive controls adequate to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented, and the food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the FD&amp;C Act, to comply with 21 CFR 117.135(a)(1).\u003C\u002Fp>\u003Cp>Your facility manufactures RTE cheesecake and cake roll products which are exposed to the environment after baking and at all steps through to packaging, where they may become contaminated with environmental pathogens such as \u003Cem>L. monocytogenes\u003C\u002Fem>. Your RTE cheesecake and cake roll products do not receive any further lethal treatment after baking or otherwise include a control measure that would significantly minimize the pathogen. Your hazard analysis identifies the hazard of environmental pathogens (specifically, \u003Cem>Listeria\u003C\u002Fem> spp. and \u003Cem>Salmonella\u003C\u002Fem> spp.) as reasonably likely to occur and identifies pathogen contamination as a hazard requiring a sanitation control. However, as evidenced by environmental findings of \u003Cem>L. monocytogenes\u003C\u002Fem> in your facility, you did not implement sanitation controls adequate to ensure that your facility is maintained in a sanitary condition to significantly minimize or prevent the hazard of environmental pathogen \u003Cem>L. monocytogenes\u003C\u002Fem>, as required by 21 CFR 117.135(a)(1) and (c)(3), and as further discussed below.\u003C\u002Fp>\u003Cp>\u003Cem>L. monocytogenes\u003C\u002Fem> is a pathogenic bacterium that is widespread in the environment and may be introduced into a food processing facility from raw materials, humans, or equipment. Without adequate controls, it can proliferate in food processing facilities and subsequently contaminate food. Therefore, it is essential to identify the areas of the food processing plant where this organism is able to grow and survive and to apply controls or take corrective actions as necessary to eradicate the organism. Consuming foods contaminated with \u003Cem>L. monocytogenes\u003C\u002Fem> can lead to a severe, sometimes life-threatening illness called listeriosis, a foodborne illness, which is a major public health concern due to the severity of the disease, its high case-fatality rate, its long incubation time, and its tendency to affect individuals with underlying conditions.\u003C\u002Fp>\u003Cp>FDA laboratory analysis of the environmental sample #\u003Cstrong>(b)(4)\u003C\u002Fstrong> collected at your facility on January 13, 2025, confirmed that \u003Cstrong>(b)(4)\u003C\u002Fstrong> environmental swabs were positive for L. monocytogenes. FDA laboratory analysis also confirmed that \u003Cstrong>(b)(4)\u003C\u002Fstrong> environmental swabs collected at your facility on January 14, 2025, were positive for \u003Cem>L. monocytogenes\u003C\u002Fem>. The positive swabs were recovered from food and non-food contact surface areas in your production environment, including but not limited to the metal conveyor belt on the cooling line in the Cake Roll Cooling Room, the table in your Cheesecake Depanning Room, several floor drains in your Cheesecake Depanning room, and multiple floor holes with water in your Cheesecake Packing Room and Cheesecake Depanning Room. Additionally, in parallel to the FDA swabbing, you collected duplicate environmental swabs on January 13, 2025, and January 14, 2025, which isolated \u003Cem>L. monocytogenes\u003C\u002Fem> in the Cheesecake production area from \u003Cstrong>(b)(4)\u003C\u002Fstrong> swabs, including a table, a floor mat, floors, drains, and doorways.\u003C\u002Fp>\u003Cp>Whole genome sequencing (WGS) analysis was conducted on the above referenced \u003Cem>L. monocytogenes\u003C\u002Fem> isolates obtained from the FDA environmental swabs and collected on January 13 and 14, 2025. Based on the results of the WGS analysis, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> isolates represent a single unique strain of \u003Cem>L. monocytogenes\u003C\u002Fem> and does not match, nor cluster with, any other isolates in the NCBI database. We advised you of the importance of these WGS results via a conference call on March 26, 2025.\u003C\u002Fp>\u003Cp>The presence of \u003Cem>L. monocytogenes\u003C\u002Fem> in your facility demonstrates that your sanitation procedures have been inadequate to significantly minimize or prevent \u003Cem>L. monocytogenes\u003C\u002Fem> in your facility. Appropriate control of \u003Cem>L. monocytogenes\u003C\u002Fem> in a food processing environment requires knowledge of the unique characteristics of the organism and implementation of the corresponding hygienic practices necessary to control this pathogen. Our findings indicate that your firm is neither achieving satisfactory control against the presence of \u003Cem>L. monocytogenes\u003C\u002Fem> within your facility nor implementing effective methods and controls to eliminate this human pathogen or minimize exposure to food and food-contact surfaces. Once \u003Cem>L. monocytogenes\u003C\u002Fem> is established in a production area, personnel or equipment can facilitate the pathogen’s movement and contamination of food-contact surfaces and finished product. It is essential to identify the areas of the food processing plant where this organism is able to survive and grow (i.e., harborage sites), and to apply controls or take corrective actions as necessary to eradicate the organism by rendering these areas unable to support the survival and growth of the organism and prevent the organism from being re-established in such sites.\u003C\u002Fp>\u003Cp>During our inspection your firm stated, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. All cake roll products manufactured that week were quarantined for destruction. In response to these findings, you halted production, conducted a root cause analysis that included enhanced environmental swabbing, and deep cleaned and sanitized. During your enhanced environmental swabbing \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On January 6, 2025, you resumed cake roll production. On February 17-18, 2025, your firm destroyed \u003Cstrong>(b)(4)\u003C\u002Fstrong> pounds of cake rolls manufactured the week of October 14-21, 2024, and our Investigator observed one day of this destruction on February 18, 2025.\u003C\u002Fp>\u003Cp>We acknowledge your voluntary corrections made during the inspection, in which your firm suspended production for three days, from January 15-17, 2025, to conduct enhanced sanitizing on your equipment and production room along with follow-up verification swabbing, per your firm’s environmental monitoring program SOP. Ultimately, on January 24, 2025, your firm ceased all cake roll production. Your firm removed all cake roll production equipment and cooling equipment from your production area. FDA’s investigator visually confirmed the removal of this equipment on February 4, 2025.\u003C\u002Fp>\u003Cp>Additionally, we acknowledge your responses to the FDA-483 dated March 14, 2025, March 20, 2025, and April 11, 2025. Your response included a copy of your revised drafted environmental monitoring program in which you will routinely conduct environmental swabbing on food contact surfaces. Your firm also provided a draft startup plan which includes enhanced sanitation and sampling “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” On April 11, 2025, your firm provided the destruction documents for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cases of cake rolls products manufactured on January 13, 2025 through January 15, 2025 and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cases of cheesecake products manufactured on January 14, 2025.\u003C\u002Fp>\u003Cp>Given the positive \u003Cem>L. monocytogenes\u003C\u002Fem> findings in your processing environment and failures of Current Good Manufacturing Practice, Hazard Analysis and Risk-Based Preventive Controls, we continue to be concerned about your ability to maintain a sanitary environment. We recommend that you continue to identify potential harborage sites and source(s) of the organism in your processing environment and implement the necessary methods and controls to ensure \u003Cem>L. monocytogenes\u003C\u002Fem> does not contaminate your environment or your RTE food products. Your sanitation procedures should be revised to include intensified swabbing to identify sources and routes of contamination to prevent the establishment of \u003Cem>L. monocytogenes\u003C\u002Fem> in your processing environment.\u003C\u002Fp>\u003Cp>We will verify the effectiveness of your corrective actions and your ability to maintain a sanitary environment during our next inspection.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Current Good Manufacturing Practice (Subpart B):\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>2. Your plant was not constructed and designed to facilitate maintenance and sanitary operations for food-production purposes, as required by 21 CFR 117.20(b).\u003C\u002Fp>\u003Cp>Specifically, on 01\u002F13\u002F2025, we observed condensation accumulated on the underside of a cooling unit suspended above the cake roll production line dripping liquid onto exposed confectioner’s sugar held in plastic bins that was being added to the top of ready-to-eat cake rolls.\u003C\u002Fp>\u003Cp>We acknowledge your voluntary corrections made during the inspection which included removing all equipment from the cake roll packaging room, indefinitely suspending your cake roll production, and committing to destroying all cake roll products.\u003C\u002Fp>\u003Cp>Additionally, we acknowledge your responses to FDA-483, which detailed the corrective actions that you took to address the dripping condensate. Your corrective actions included stopping the production line, removing all materials from the line, destroying all food contact product in the plastic bin, cleaning and physically drying the production line and overhead area, repositioning the bins for sugar away from the location the condensate drip was identified, and purchasing \u003Cstrong>(b)(4)\u003C\u002Fstrong> fans of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cfm and placed them in the overhead crawlspace at angles to deter further condensation.\u003C\u002Fp>\u003Cp>Your firm intends to retrain all key personnel on GMPs including monitoring for condensation and you intend to appropriately document and provide the training records once the plant is back in operation. Your firm also removed the evaporators units in the area and installed \u003Cstrong>(b)(4)\u003C\u002Fstrong> new \u003Cstrong>(b)(4)\u003C\u002Fstrong>-ton refrigeration units each with placement at the side of the room perimeters and not over food production.\u003C\u002Fp>\u003Cp>We will verify the adequacy and implementation of your corrective actions during our next inspection.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address these violations may result in legal action by the FDA including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\u003Cp>\u003Cstrong>In addition to the violations described above, we offer the following comment:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>FDA laboratory analysis of the environmental sample \u003Cstrong>(b)(4)\u003C\u002Fstrong> collected at your facility on January 13, 2025, confirmed that \u003Cstrong>(b)(4)\u003C\u002Fstrong> environmental swabs were positive for \u003Cem>Listeria innocua\u003C\u002Fem> (a non-pathogenic Listeria species). The positive swabs were recovered from non-food contact surfaces in your production environment, including but not limited to the floor, floor holes, floor drain in your Cake Roll Cooling Room and Cake Roll Packing Room. Additionally, FDA laboratory analysis of the environmental sample \u003Cstrong>(b)(4)\u003C\u002Fstrong> collected at your facility on January 14, 2025, confirmed that \u003Cstrong>(b)(4)\u003C\u002Fstrong> environmental swabs were positive for \u003Cem>Listeria welshimeri\u003C\u002Fem> (a non-pathogenic Listeria species). The positive swabs were recovered from food and non-food contact surfaces in your production environment, including but not limited to the table, cheesecake cutter operator buttons and emergency stop button, floors, floor drain and door in your Cheesecake De-panning Room and Cheesecake Packing Room. The presence of Listeria species such as \u003Cem>Listeria innocua\u003C\u002Fem> and \u003Cem>Listeria welshimeri\u003C\u002Fem> suggests that conditions also are suitable for survival and\u002For growth of \u003Cem>L. monocytogenes\u003C\u002Fem>, which, as noted above, has been found in your facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Please notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Dana Lewis, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Dana Lewis via email at: Dana.Lewis@fda.hhs.gov. Please include reference CMS #706334 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD MBA\u003Cbr>Acting Director\u003Cbr>Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC DELIVERY\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Jeffery B. Liddy\n\nRecipient Title\n\nPresident\n\nThe Father's Table, LLC\n\n2301 E Lake Mary Blvd\n\nSanford, FL 32773-7143\n\nUnited States\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nNovember 28, 2025\nWARNING LETTER\nCMS #706334\nDear Mr. Liddy:\nThe U.S. Food and Drug Administration (FDA) inspected your food manufacturing facility, The Father’s Table, LLC, located at 2301 E Lake Mary Blvd, Sanford, FL 32773, from January 13, 2025, through February 13, 2025. Your firm manufactures ready-to-eat (RTE) cheesecakes and cake roll products.\nDuring our inspection, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventative Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Additionally, FDA collected environmental samples (i.e., swabs) from various areas in your processing facility. FDA laboratory analyses of the environmental swabs found the presence of Listeria monocytogenes (L. monocytogenes), a human pathogen, in your facility.\nBased on FDA’s inspectional findings and analytical results revealing L. monocytogenes in your production environment, we have determined that your RTE food products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls’ provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of 21 CFR Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP & PC rule through links in FDA’s home page at www.fda.gov.\nAt the conclusion of the inspection, FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations, listing deviations found at your facility. We received your firm’s responses to the FDA-483 on March 14, 2025, March 20, 2025, and April 11, 2025, describing corrective actions taken by your firm. After reviewing the inspectional findings and your responses, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility. We discuss your response below.\nHazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C):\n1. You did not implement preventive controls adequate to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented, and the food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the FD&C Act, to comply with 21 CFR 117.135(a)(1).\nYour facility manufactures RTE cheesecake and cake roll products which are exposed to the environment after baking and at all steps through to packaging, where they may become contaminated with environmental pathogens such as L. monocytogenes. Your RTE cheesecake and cake roll products do not receive any further lethal treatment after baking or otherwise include a control measure that would significantly minimize the pathogen. Your hazard analysis identifies the hazard of environmental pathogens (specifically, Listeria spp. and Salmonella spp.) as reasonably likely to occur and identifies pathogen contamination as a hazard requiring a sanitation control. However, as evidenced by environmental findings of L. monocytogenes in your facility, you did not implement sanitation controls adequate to ensure that your facility is maintained in a sanitary condition to significantly minimize or prevent the hazard of environmental pathogen L. monocytogenes, as required by 21 CFR 117.135(a)(1) and (c)(3), and as further discussed below.\nL. monocytogenes is a pathogenic bacterium that is widespread in the environment and may be introduced into a food processing facility from raw materials, humans, or equipment. Without adequate controls, it can proliferate in food processing facilities and subsequently contaminate food. Therefore, it is essential to identify the areas of the food processing plant where this organism is able to grow and survive and to apply controls or take corrective actions as necessary to eradicate the organism. Consuming foods contaminated with L. monocytogenes can lead to a severe, sometimes life-threatening illness called listeriosis, a foodborne illness, which is a major public health concern due to the severity of the disease, its high case-fatality rate, its long incubation time, and its tendency to affect individuals with underlying conditions.\nFDA laboratory analysis of the environmental sample #(b)(4) collected at your facility on January 13, 2025, confirmed that (b)(4) environmental swabs were positive for L. monocytogenes. FDA laboratory analysis also confirmed that (b)(4) environmental swabs collected at your facility on January 14, 2025, were positive for L. monocytogenes. The positive swabs were recovered from food and non-food contact surface areas in your production environment, including but not limited to the metal conveyor belt on the cooling line in the Cake Roll Cooling Room, the table in your Cheesecake Depanning Room, several floor drains in your Cheesecake Depanning room, and multiple floor holes with water in your Cheesecake Packing Room and Cheesecake Depanning Room. Additionally, in parallel to the FDA swabbing, you collected duplicate environmental swabs on January 13, 2025, and January 14, 2025, which isolated L. monocytogenes in the Cheesecake production area from (b)(4) swabs, including a table, a floor mat, floors, drains, and doorways.\nWhole genome sequencing (WGS) analysis was conducted on the above referenced L. monocytogenes isolates obtained from the FDA environmental swabs and collected on January 13 and 14, 2025. Based on the results of the WGS analysis, the (b)(4) isolates represent a single unique strain of L. monocytogenes and does not match, nor cluster with, any other isolates in the NCBI database. We advised you of the importance of these WGS results via a conference call on March 26, 2025.\nThe presence of L. monocytogenes in your facility demonstrates that your sanitation procedures have been inadequate to significantly minimize or prevent L. monocytogenes in your facility. Appropriate control of L. monocytogenes in a food processing environment requires knowledge of the unique characteristics of the organism and implementation of the corresponding hygienic practices necessary to control this pathogen. Our findings indicate that your firm is neither achieving satisfactory control against the presence of L. monocytogenes within your facility nor implementing effective methods and controls to eliminate this human pathogen or minimize exposure to food and food-contact surfaces. Once L. monocytogenes is established in a production area, personnel or equipment can facilitate the pathogen’s movement and contamination of food-contact surfaces and finished product. It is essential to identify the areas of the food processing plant where this organism is able to survive and grow (i.e., harborage sites), and to apply controls or take corrective actions as necessary to eradicate the organism by rendering these areas unable to support the survival and growth of the organism and prevent the organism from being re-established in such sites.\nDuring our inspection your firm stated, (b)(4). All cake roll products manufactured that week were quarantined for destruction. In response to these findings, you halted production, conducted a root cause analysis that included enhanced environmental swabbing, and deep cleaned and sanitized. During your enhanced environmental swabbing (b)(4). On January 6, 2025, you resumed cake roll production. On February 17-18, 2025, your firm destroyed (b)(4) pounds of cake rolls manufactured the week of October 14-21, 2024, and our Investigator observed one day of this destruction on February 18, 2025.\nWe acknowledge your voluntary corrections made during the inspection, in which your firm suspended production for three days, from January 15-17, 2025, to conduct enhanced sanitizing on your equipment and production room along with follow-up verification swabbing, per your firm’s environmental monitoring program SOP. Ultimately, on January 24, 2025, your firm ceased all cake roll production. Your firm removed all cake roll production equipment and cooling equipment from your production area. FDA’s investigator visually confirmed the removal of this equipment on February 4, 2025.\nAdditionally, we acknowledge your responses to the FDA-483 dated March 14, 2025, March 20, 2025, and April 11, 2025. Your response included a copy of your revised drafted environmental monitoring program in which you will routinely conduct environmental swabbing on food contact surfaces. Your firm also provided a draft startup plan which includes enhanced sanitation and sampling “(b)(4).” On April 11, 2025, your firm provided the destruction documents for the (b)(4) cases of cake rolls products manufactured on January 13, 2025 through January 15, 2025 and (b)(4) cases of cheesecake products manufactured on January 14, 2025.\nGiven the positive L. monocytogenes findings in your processing environment and failures of Current Good Manufacturing Practice, Hazard Analysis and Risk-Based Preventive Controls, we continue to be concerned about your ability to maintain a sanitary environment. We recommend that you continue to identify potential harborage sites and source(s) of the organism in your processing environment and implement the necessary methods and controls to ensure L. monocytogenes does not contaminate your environment or your RTE food products. Your sanitation procedures should be revised to include intensified swabbing to identify sources and routes of contamination to prevent the establishment of L. monocytogenes in your processing environment.\nWe will verify the effectiveness of your corrective actions and your ability to maintain a sanitary environment during our next inspection.\nCurrent Good Manufacturing Practice (Subpart B):\n2. Your plant was not constructed and designed to facilitate maintenance and sanitary operations for food-production purposes, as required by 21 CFR 117.20(b).\nSpecifically, on 01\u002F13\u002F2025, we observed condensation accumulated on the underside of a cooling unit suspended above the cake roll production line dripping liquid onto exposed confectioner’s sugar held in plastic bins that was being added to the top of ready-to-eat cake rolls.\nWe acknowledge your voluntary corrections made during the inspection which included removing all equipment from the cake roll packaging room, indefinitely suspending your cake roll production, and committing to destroying all cake roll products.\nAdditionally, we acknowledge your responses to FDA-483, which detailed the corrective actions that you took to address the dripping condensate. Your corrective actions included stopping the production line, removing all materials from the line, destroying all food contact product in the plastic bin, cleaning and physically drying the production line and overhead area, repositioning the bins for sugar away from the location the condensate drip was identified, and purchasing (b)(4) fans of (b)(4) cfm and placed them in the overhead crawlspace at angles to deter further condensation.\nYour firm intends to retrain all key personnel on GMPs including monitoring for condensation and you intend to appropriately document and provide the training records once the plant is back in operation. Your firm also removed the evaporators units in the area and installed (b)(4) new (b)(4)-ton refrigeration units each with placement at the side of the room perimeters and not over food production.\nWe will verify the adequacy and implementation of your corrective actions during our next inspection.\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address these violations may result in legal action by the FDA including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\nIn addition to the violations described above, we offer the following comment:\nFDA laboratory analysis of the environmental sample (b)(4) collected at your facility on January 13, 2025, confirmed that (b)(4) environmental swabs were positive for Listeria innocua (a non-pathogenic Listeria species). The positive swabs were recovered from non-food contact surfaces in your production environment, including but not limited to the floor, floor holes, floor drain in your Cake Roll Cooling Room and Cake Roll Packing Room. Additionally, FDA laboratory analysis of the environmental sample (b)(4) collected at your facility on January 14, 2025, confirmed that (b)(4) environmental swabs were positive for Listeria welshimeri (a non-pathogenic Listeria species). The positive swabs were recovered from food and non-food contact surfaces in your production environment, including but not limited to the table, cheesecake cutter operator buttons and emergency stop button, floors, floor drain and door in your Cheesecake De-panning Room and Cheesecake Packing Room. The presence of Listeria species such as Listeria innocua and Listeria welshimeri suggests that conditions also are suitable for survival and\u002For growth of L. monocytogenes, which, as noted above, has been found in your facility.\nPlease notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nPlease send your reply to the Food and Drug Administration, Attention: Dana Lewis, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Dana Lewis via email at: Dana.Lewis@fda.hhs.gov. Please include reference CMS #706334 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD MBA\nActing Director\nOffice of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","The Father's Table, LLC","fathers-table-llc-706334-11282025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffathers-table-llc-706334-11282025","2026-10-26T08:08:40.27818+00:00","2026-03-03","706334","Food & Beverages","Mr. Jeffery B. Liddy","2026-08-19T04:53:58.788+00:00","VIA ELECTRONIC DELIVERY","2025-11-28",{"id":54,"raw":55,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":19,"issuing_office":59,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":19,"reference_number":19,"action_taken_date":69,"medical_device_id":19,"response_letter_date":19},2879,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2022-02-09T20:00:00Z\">02\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-09T05:00:00Z\">02\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Femeralds-triangle-llc-625360-02092022\">Emerald&#039;s Triangle LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Richard Johnston\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Emerald's Triangle LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11131 Highway 49 North, Unit 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brookland\u003C\u002Fspan>, \u003Cspan>AR\u003C\u002Fspan> \u003Cspan>72417\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:getkevin@emmd.com\"> getkevin@emmd.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 9, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Johnston:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Emerald’s Triangle LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States EMERALD’S Custom Vape Juice STRAWBERRY 6mg e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 100 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200439, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>CC: getrich@emerald.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nRichard Johnston\n\nRecipient Title\n\nOwner\n\nEmerald's Triangle LLC\n\n11131 Highway 49 North, Unit 1\n\nBrookland, AR 72417\n\nUnited States\n\ngetkevin@emmd.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nFebruary 9, 2022\n\nWARNING LETTER\n\nDear Mr. Johnston:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Emerald’s Triangle LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States EMERALD’S Custom Vape Juice STRAWBERRY 6mg e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 100 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200439, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nCC: getrich@emerald.com","Emerald's Triangle LLC","emeralds-triangle-llc-625360-02092022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Femeralds-triangle-llc-625360-02092022","2026-10-26T08:08:35.027505+00:00","2022-02-09","625360","Tobacco","Richard Johnston","2026-08-20T02:12:10.409+00:00","VIA UPS and Electronic Mail",{"id":76,"raw":77,"subject":82,"body_html":83,"body_text":84,"firm_name":85,"letter_id":86,"created_at":87,"fei_number":19,"letter_url":88,"updated_at":89,"action_type":22,"case_status":23,"posted_date":90,"marcs_cms_no":91,"product_type":92,"closeout_date":19,"issuing_office":81,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":19,"reference_number":19,"action_taken_date":96,"medical_device_id":19,"response_letter_date":19},1924,[78,79,80,81,82,13,13,13],"\u003Ctime datetime=\"2023-08-22T13:20:00Z\">08\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-18T04:00:00Z\">08\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnatures-innovation-inc-648560-08182023\">Nature’s Innovation, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>William S. Carlson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Nature’s Innovation, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5317 Palmero Court\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Buford\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30518\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@naturesinnovation.com\"> info@naturesinnovation.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 18, 2023\u003C\u002Fp>\n\n\u003Cp>RE: 648560\u003C\u002Fp>\n\n\u003Cp>Dear William Carlson:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.naturasil.com in July 2023. We also reviewed your social media websites at www.instagram.com\u002Fnaturasil\u002F and www.facebook.com\u002FNaturasil\u002F, where you direct consumers to your website, www.naturasil.com, to purchase your products. The FDA has observed that your website offers your “Naturasil Molluscum Treatment Kit”\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and “Naturasil Shingles” products for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Molluscum contagiosum is not a condition amenable to self-diagnosis and treatment, and there are no legally marketed over-the-counter (OTC) drug products to treat this condition. Molluscum contagiosum is a viral skin infection characterized by small, raised lesions on the skin that are known as Mollusca. Molluscum affects both children and adults; however, it is more common in children. In healthy individuals, the lesions usually disappear spontaneously within 6 to 12 months, although in some cases, it could take years to resolve. In sexually active individuals, the lesions found in the genital region are considered a sexually transmitted disease\u002Finfection (STD\u002FSTI). In addition, patients with new or existing skin lesions should seek out a healthcare professional to be evaluated. A healthcare professional is needed to rule out the possibility of a more serious condition, such as, skin cancer, fungal infection, and for the genitalia, anogenital warts. Your “Naturasil Molluscum Treatment Kit” is especially concerning from a public health perspective because it is marketed for use in children. In addition, FDA is concerned that people are forgoing or delaying proper diagnosis and treatment of a potentially serious, undiagnosed health condition by purchasing and using an unapproved drug product claiming to treat molluscum contagiosum.\u003C\u002Fp>\n\n\u003Cp>Your “Naturasil Shingles” product is concerning for various reasons. Shingles is a serious condition that is not amenable to either diagnosis or treatment by a lay person, and there are no legally marketed OTC drug products to treat this condition. Treatment of shingles requires antiviral therapy, and early treatment is key to promote healing of the rash and reduce the severity and duration of pain. A person with shingles can potentially spread the varicella-zoster virus to others. Furthermore, FDA is concerned that people who use an unapproved drug product claiming to treat shingles are putting themselves at risk for developing serious complications, e.g., postherpetic neuralgia (long-term nerve pain), herpes zoster ophthalmicus (which can lead to vision loss), and skin infections.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your websites, your “Naturasil Molluscum Treatment Kit” and “Natural Shingles” products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your websites that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Naturasil Molluscum Treatment Kit\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for “Naturasil Molluscum Treatment Kit,” https:\u002F\u002Fwww.naturasil.com\u002Fpages\u002Fmolluscum-contagiosum-treatment-kit?_pos=12&amp;_sid=acf8ae577&amp;_ss=r:\u003Cbr>\n• “NATURASIL FOR MOLLUSCUM IS THE NUMBER 1 All Natural, No Acids, Pain-Free Remedy for Children and Adults, Made in the USA. Parent Approved!”\u003Cbr>\n• “Naturasil for Molluscum Treatment Kit . . . Get rid of Molluscum at home with this PAIN-FREE BREAKTHROUGH 100% Natural Molluscum Contagiosum Treatment. CHILD-SAFE (2 years old &amp; above) Causes Molluscum to dry up and flake away painlessly over time.”\u003Cbr>\n• “Effectively &amp; gently clears Molluscum bumps Relieves itching &amp; discomfort”\u003Cbr>\n• “Naturasil for Molluscum Treatment Kit for Children and Adults… Best for treating Genitals and other sensitive areas and children or adults with large or severe Molluscum outbreaks.”\u003C\u002Fp>\n\n\u003Cp>From a September 6, 2022 blog post entitled, “MOLLUSCUM CONTAGIOSUM | SIGNS AND SYMPTOMS OF AN INFECTION,” https:\u002F\u002Fwww.naturasil.com\u002Fblogs\u002Fnaturasil-blogs\u002Fmolluscum-contagiosum-signs-symptoms?_pos=8&amp;_sid=c37dd889d&amp;_ss=r:\u003Cbr>\n• “Regardless, effective natural remedies, such as the Naturasil Molluscum Contagiosum Treatments are designed to penetrate viral cells to quicken your recovery time.”\u003C\u002Fp>\n\n\u003Cp>From a June 10, 2022 blog post entitled, “Natural Treatment Options for Molluscum Contagiosum,” https:\u002F\u002Fwww.naturasil.com\u002Fblogs\u002Fnaturasil-blogs\u002Fnatural-treatment-options-for-molluscum-contagiosum?_pos=7&amp;_sid=c37dd889d&amp;_ss=r:\u003Cbr>\n• “Naturasil's Molluscum Contagiosum Treatment was constructed with the most potent ingredients throughout the herbal industry. Each compound injects a vast array of nutrients capable of hindering the health and development of the molluscum virus.”\u003Cbr>\n• “Naturasil for Molluscum is a completely natural treatment solution that eradicates this awful condition often found in children quickly and safely without the use of harsh chemicals.”\u003C\u002Fp>\n\n\u003Cp>On your Facebook social media page https:\u002F\u002Fwww.facebook.com\u002FNaturasil\u002F:\u003Cbr>\n• March 15, 2023 post: “Most Trusted Molluscum Brand Effectively &amp; #gently #clears #Molluscum #bumps #Relieves #itching &amp; #discomfort”\u003Cbr>\n• October 8, 2022 post – Your post includes some of the following hashtags: “#molluscumcontagiosum,” “#kidsafe,” “#natural,” “#remedy,” “#treatment” with an image of your “Naturasil Molluscum Treatment Kit” product and text that reads “I wish I could share before and after photos, his molluscum is almost gone with a few more treatments it will be . . . My 3 year [old] has had it for 1.5 years and nothing worked. Thank you soo [sic] much Naturasil.”\u003C\u002Fp>\n\n\u003Cp>On your Instagram social media page https:\u002F\u002Fwww.instagram.com\u002Fnaturasil\u002F?hl=en:\u003Cbr>\n• August 4, 2022 post – Your post includes an image of your “Naturasil Molluscum Treatment Kit” product and text that reads “It works! We’ve been using the product for a few weeks and I can definitely see an improvement in my daughter’s sports. Some are shrinking and others are drying up. We have had the best results when applying it 4-5 times a day. It requires patience, but is the only thing I’ve seen that works!”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Naturasil Shingles\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for “Naturasil Shingles,” https:\u002F\u002Fwww.naturasil.com\u002Fpages\u002Fshingles-15ml:\u003Cbr>\n• “Naturasil for Shingles assists the body in reducing and eliminating shingles outbreaks naturally and effectively, without the harmful side effects found in many shingles treatment drugs, through a topical application that is absorbed into the skin at the site of the outbreak.”\u003Cbr>\n• “The active components of our shingles treatments are high levels of neral, geraniol, alpha-terpinenes, and linalool. All anti-viral and anti-inflammatory compounds are found in Melissa Officinalis, melaleuca alternifolia, agathophyllum aromatica, and other critical anti-viral plant extracts. These compounds have anti-viral properties and effectively combat the herpes zoster virus that causes shingles.”\u003Cbr>\n• “END THE SHINGLE NIGHTMARE NOW. Get the all-natural, #1 REMEDY, complete package for treating YOUR Shingles.”\u003C\u002Fp>\n\n\u003Cp>Your “Naturasil Molluscum Treatment Kit” and “Natural Shingles” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these products.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Furman\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On your website, www.naturasil.com, you state that your “Naturasil Molluscum Treatment Kit” product consists of your “Naturasil Molluscum Topical Liquid” and your “Naturasil Molluscum Relief Soap” products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We recognize that the “Naturasil Molluscum Treatment Kit” and “Naturasil Shingles” labeling describes the products as being “homeopathic.”\u003C\u002Fp>\n\n\u003Cp>First, we note that under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States without the required FDA approval. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your above-mentioned drugs include non-homeopathic ingredients that, although listed as “inactive ingredients,” are considered active ingredients under 21 C.F.R. 201.66(b)(2) because they are promoted on your website in various places with claims to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or any function of the body. These other active ingredients are not listed in dilutions and at least some are not listed in the HPUS, and thus these products fall outside the scope of products addressed in this guidance. Notwithstanding, even if your above listed products were considered “homeopathic drug products\" under this guidance, these products would fall under the guidance’s categories of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health, and thus intends to prioritize for enforcement and regulatory actions.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nWilliam S. Carlson\n\nRecipient Title\n\nCEO\n\nNature’s Innovation, Inc.\n\n5317 Palmero Court\n\nBuford, GA 30518\n\nUnited States\n\ninfo@naturesinnovation.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nAugust 18, 2023\n\nRE: 648560\n\nDear William Carlson:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.naturasil.com in July 2023. We also reviewed your social media websites at www.instagram.com\u002Fnaturasil\u002F and www.facebook.com\u002FNaturasil\u002F, where you direct consumers to your website, www.naturasil.com, to purchase your products. The FDA has observed that your website offers your “Naturasil Molluscum Treatment Kit”1 and “Naturasil Shingles” products for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act.\n\nMolluscum contagiosum is not a condition amenable to self-diagnosis and treatment, and there are no legally marketed over-the-counter (OTC) drug products to treat this condition. Molluscum contagiosum is a viral skin infection characterized by small, raised lesions on the skin that are known as Mollusca. Molluscum affects both children and adults; however, it is more common in children. In healthy individuals, the lesions usually disappear spontaneously within 6 to 12 months, although in some cases, it could take years to resolve. In sexually active individuals, the lesions found in the genital region are considered a sexually transmitted disease\u002Finfection (STD\u002FSTI). In addition, patients with new or existing skin lesions should seek out a healthcare professional to be evaluated. A healthcare professional is needed to rule out the possibility of a more serious condition, such as, skin cancer, fungal infection, and for the genitalia, anogenital warts. Your “Naturasil Molluscum Treatment Kit” is especially concerning from a public health perspective because it is marketed for use in children. In addition, FDA is concerned that people are forgoing or delaying proper diagnosis and treatment of a potentially serious, undiagnosed health condition by purchasing and using an unapproved drug product claiming to treat molluscum contagiosum.\n\nYour “Naturasil Shingles” product is concerning for various reasons. Shingles is a serious condition that is not amenable to either diagnosis or treatment by a lay person, and there are no legally marketed OTC drug products to treat this condition. Treatment of shingles requires antiviral therapy, and early treatment is key to promote healing of the rash and reduce the severity and duration of pain. A person with shingles can potentially spread the varicella-zoster virus to others. Furthermore, FDA is concerned that people who use an unapproved drug product claiming to treat shingles are putting themselves at risk for developing serious complications, e.g., postherpetic neuralgia (long-term nerve pain), herpes zoster ophthalmicus (which can lead to vision loss), and skin infections.\n\nUnapproved New Drugs\n\nBased on a review of your websites, your “Naturasil Molluscum Treatment Kit” and “Natural Shingles” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims from your websites that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\nNaturasil Molluscum Treatment Kit\n\nOn the product webpage for “Naturasil Molluscum Treatment Kit,” https:\u002F\u002Fwww.naturasil.com\u002Fpages\u002Fmolluscum-contagiosum-treatment-kit?_pos=12&_sid=acf8ae577&_ss=r:\n\n• “NATURASIL FOR MOLLUSCUM IS THE NUMBER 1 All Natural, No Acids, Pain-Free Remedy for Children and Adults, Made in the USA. Parent Approved!”\n\n• “Naturasil for Molluscum Treatment Kit . . . Get rid of Molluscum at home with this PAIN-FREE BREAKTHROUGH 100% Natural Molluscum Contagiosum Treatment. CHILD-SAFE (2 years old & above) Causes Molluscum to dry up and flake away painlessly over time.”\n\n• “Effectively & gently clears Molluscum bumps Relieves itching & discomfort”\n\n• “Naturasil for Molluscum Treatment Kit for Children and Adults… Best for treating Genitals and other sensitive areas and children or adults with large or severe Molluscum outbreaks.”\n\nFrom a September 6, 2022 blog post entitled, “MOLLUSCUM CONTAGIOSUM | SIGNS AND SYMPTOMS OF AN INFECTION,” https:\u002F\u002Fwww.naturasil.com\u002Fblogs\u002Fnaturasil-blogs\u002Fmolluscum-contagiosum-signs-symptoms?_pos=8&_sid=c37dd889d&_ss=r:\n\n• “Regardless, effective natural remedies, such as the Naturasil Molluscum Contagiosum Treatments are designed to penetrate viral cells to quicken your recovery time.”\n\nFrom a June 10, 2022 blog post entitled, “Natural Treatment Options for Molluscum Contagiosum,” https:\u002F\u002Fwww.naturasil.com\u002Fblogs\u002Fnaturasil-blogs\u002Fnatural-treatment-options-for-molluscum-contagiosum?_pos=7&_sid=c37dd889d&_ss=r:\n\n• “Naturasil's Molluscum Contagiosum Treatment was constructed with the most potent ingredients throughout the herbal industry. Each compound injects a vast array of nutrients capable of hindering the health and development of the molluscum virus.”\n\n• “Naturasil for Molluscum is a completely natural treatment solution that eradicates this awful condition often found in children quickly and safely without the use of harsh chemicals.”\n\nOn your Facebook social media page https:\u002F\u002Fwww.facebook.com\u002FNaturasil\u002F:\n\n• March 15, 2023 post: “Most Trusted Molluscum Brand Effectively & #gently #clears #Molluscum #bumps #Relieves #itching & #discomfort”\n\n• October 8, 2022 post – Your post includes some of the following hashtags: “#molluscumcontagiosum,” “#kidsafe,” “#natural,” “#remedy,” “#treatment” with an image of your “Naturasil Molluscum Treatment Kit” product and text that reads “I wish I could share before and after photos, his molluscum is almost gone with a few more treatments it will be . . . My 3 year [old] has had it for 1.5 years and nothing worked. Thank you soo [sic] much Naturasil.”\n\nOn your Instagram social media page https:\u002F\u002Fwww.instagram.com\u002Fnaturasil\u002F?hl=en:\n\n• August 4, 2022 post – Your post includes an image of your “Naturasil Molluscum Treatment Kit” product and text that reads “It works! We’ve been using the product for a few weeks and I can definitely see an improvement in my daughter’s sports. Some are shrinking and others are drying up. We have had the best results when applying it 4-5 times a day. It requires patience, but is the only thing I’ve seen that works!”\n\nNaturasil Shingles\n\nOn the product webpage for “Naturasil Shingles,” https:\u002F\u002Fwww.naturasil.com\u002Fpages\u002Fshingles-15ml:\n\n• “Naturasil for Shingles assists the body in reducing and eliminating shingles outbreaks naturally and effectively, without the harmful side effects found in many shingles treatment drugs, through a topical application that is absorbed into the skin at the site of the outbreak.”\n\n• “The active components of our shingles treatments are high levels of neral, geraniol, alpha-terpinenes, and linalool. All anti-viral and anti-inflammatory compounds are found in Melissa Officinalis, melaleuca alternifolia, agathophyllum aromatica, and other critical anti-viral plant extracts. These compounds have anti-viral properties and effectively combat the herpes zoster virus that causes shingles.”\n\n• “END THE SHINGLE NIGHTMARE NOW. Get the all-natural, #1 REMEDY, complete package for treating YOUR Shingles.”\n\nYour “Naturasil Molluscum Treatment Kit” and “Natural Shingles” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these products.2 Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n__________________________\n\n1 On your website, www.naturasil.com, you state that your “Naturasil Molluscum Treatment Kit” product consists of your “Naturasil Molluscum Topical Liquid” and your “Naturasil Molluscum Relief Soap” products.\n\n2 We recognize that the “Naturasil Molluscum Treatment Kit” and “Naturasil Shingles” labeling describes the products as being “homeopathic.”\n\nFirst, we note that under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\n\nIn addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States without the required FDA approval. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your above-mentioned drugs include non-homeopathic ingredients that, although listed as “inactive ingredients,” are considered active ingredients under 21 C.F.R. 201.66(b)(2) because they are promoted on your website in various places with claims to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or any function of the body. These other active ingredients are not listed in dilutions and at least some are not listed in the HPUS, and thus these products fall outside the scope of products addressed in this guidance. Notwithstanding, even if your above listed products were considered “homeopathic drug products\" under this guidance, these products would fall under the guidance’s categories of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health, and thus intends to prioritize for enforcement and regulatory actions.","Nature’s Innovation, Inc.","natures-innovation-inc-648560-08182023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnatures-innovation-inc-648560-08182023","2026-10-26T08:09:30.91471+00:00","2023-08-22","648560","Drugs","William S. Carlson","2026-08-20T00:46:42.599+00:00","Via Email","2023-08-18",{"id":98,"raw":99,"subject":103,"body_html":104,"body_text":105,"firm_name":106,"letter_id":107,"created_at":87,"fei_number":19,"letter_url":108,"updated_at":109,"action_type":22,"case_status":23,"posted_date":110,"marcs_cms_no":111,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":112,"body_fetched_at":113,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":114,"medical_device_id":19,"response_letter_date":19},1505,[100,101,102,11,103,13,13,13],"\u003Ctime datetime=\"2024-04-30T13:20:00Z\">04\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-19T04:00:00Z\">09\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpt-sankei-medical-industries-665754-09192023\">P.T. Sankei Medical Industries\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yoshinori Koyama\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>P.T. Sankei Medical Industries\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>JL. Mordern Inustri III, Komp. BPSP A-12\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kawasan Industri Modern Cikande\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Serang\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Banten\u003C\u002Fspan> \u003Cspan>42186\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Indonesia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 19, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Koyama:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Banten, Indonesia on May 8, 2023, through May 11, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>We received a response from you dated May 24, 2023, concerning our investigator(s)’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved Device Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>You currently have a clearance for the Aneroid Sphygmomanometers\u002FMercurial Sphygmomanometers under K942543. Our inspection revealed that your firm made changes to the materials of the cleared device without submission of a new 510(k). As explained in Section C.4.1 of the guidance document \u003Cu>Deciding When to Submit a 510(k) for a Change to an Existing Device\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fu> (“510(k) Modifications Guidance”) in general, changing the material may affect the biocompatibility of the device. Thus, these changes could significantly affect the safety or effectiveness of the device and required the submission of a new 510(k). 21 CFR 807.81(a)(3)(i). Your response did not address this violation.\u003C\u002Fp>\n\n\u003Cp>Accordingly, the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency.21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Quality System Regulations (QSR) Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that this device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1.&nbsp; Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).For example:\u003C\u002Fp>\n\n\u003Cp>Your Design and Development Procedure (Document #PS-17, Revision 00) is a process for the development of new systems and products as well as existing ones in order to meet external and internal customer requirements. This procedure was not applied to the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device since design controls have not been conducted for the single use sphygmomanometer.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Design and Development Procedure; however, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide evidence of the corrective actions. For example, this should include documentation and confirmation the design controls were applied to the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device. Please provide all responses and documentation in English or with English translations.\u003C\u002Fp>\n\n\u003Cp>2.&nbsp; Failure to adequately establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21CFR 820.50. For example:\u003C\u002Fp>\n\n\u003Cp>Your Purchasing Procedure (Document #PS-04, Revision 03) requires samples made by potential suppliers to be checked by Quality Assurance (QA). However, this procedure does not detail the specified requirements, including quality requirements, that potential suppliers and contractors must meet. Further, you do not have an agreement with suppliers and\u002For contractors that requires notification of changes in the product to ensure changes do not affect quality of finished devices.\u003Cbr>\n\u003Cbr>\nWe reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Purchasing Procedure; however, the new version did not address the deficiencies noted above. Further, the supporting documents provided were not in English and could not be reviewed.\u003C\u002Fp>\n\n\u003Cp>In response to this Warning Letter, you should provide updated documentation including, but not limited to, an updated Purchasing procedure and documentation of agreements with suppliers and\u002For contractors. You should also provide evidence of the corrective actions. Please provide all responses and documentation in English or with English translations.\u003C\u002Fp>\n\n\u003Cp>3.&nbsp; Failure to adequately ensure Design History Records (DHRs) for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR and the requirements of this part, as required by 21 CFR 820.184 For example:\u003C\u002Fp>\n\n\u003Cp>Your Quality Plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Document #QP-DC-0001A, Revision 2) details the required manufacturing steps for the following procedures\u002Fwork instructions including, but not limited to: \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm’s DHRs did not include or refer to the location of the primary identification label and labeling used for each production case. Further, the procedure does not require manufacturing step documentation. Specifically, it does not require technician(s) to document manufacturing\u002Foperation steps in the production record nor utilize any forms to document the manufacturing\u002Foperation steps.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Quality Plan; however, the new version did not address the deficiencies noted above. Further, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide updated documentation including, but not limited to, updated DHRs for the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device, updates to the DHR procedures and forms. You should also provide evidence of your firm’s corrective actions. Please provide all responses and documentation in English or with English translations.\u003C\u002Fp>\n\n\u003Cp>4.&nbsp; Failure to adequately maintain device master records (DMR's), as required by 21 CFR820.181 For example:\u003C\u002Fp>\n\n\u003Cp>Your Device Master File Procedure (Document #PS-33, Revision 0) requires each DMR to include a Quality Assurance and Reference Documentation section. However, the DMR for the Sphygmomanometer is missing documentation of the Quality Assurance and Reference Document sections. Further, the DMR for the Sphygmomanometer Product has not been reviewed and approved through document controls.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The documents were not provided in English and could not be reviewed. In response to this Warning Letter, you should provide evidence of the corrective actions. For example, this should include updated documentation including, but not limited to, updated DMRs for the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device. Please provide all responses and documentation in English or with English translations.\u003C\u002Fp>\n\n\u003Cp>5.&nbsp; Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198. For example:\u003C\u002Fp>\n\n\u003Cp>Your Customer Claim Handling procedure (Document #PS-15, Revision 01) requires “preventive and corrective actions for the problem must be completed”. However, the procedure does not require review and evaluation of all complaints to determine whether an investigation is necessary, nor does it require the manufacturer to maintain a record that includes the reason no investigation was needed and the name of the individual responsible for the decision not to investigate. Further, it fails to require events meeting the definition of a complaint under 820.3(b) be evaluated to determine whether the complaint represents an event for which reporting is required under 21 CFR part 803, Medical Device Reporting. The procedure states that the Corrective and Preventive Action form is used to document customer claims. The form does not record manufacturer review and evaluation of complaint to determine whether an investigation is necessary.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Customer Claim Handling procedure; however, the new version does not address the deficiencies noted above. Further, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide evidence of updated documentation including, but not limited to, updates to the Customer Claim Handling procedures and forms as well as evidence of the corrective actions. Please provide all responses and documentation in English or with English translations.\u003C\u002Fp>\n\n\u003Cp>6.&nbsp; Failure to establish procedures for quality audits and conduct such audits to assure that the quality system complies with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22. For example:\u003C\u002Fp>\n\n\u003Cp>Your Audit Management System Procedure (Document #PS-02, Revision 03) requires audits to be conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, there is no documented evidence to show that the scheduled items\u002Fprocesses of the quality system were audited for 2022 or 2023.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The response included a version of the Audit Management System Procedure; however, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide an updated documentation including, but not limited to, documentation confirming audit performance and updated Audit Process.\u003C\u002Fp>\n\n\u003Cp>Please provide all responses and documentation in English or with English translations.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Medical Device Reporting (MDR) Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, after reviewing your firm’s MDR procedure titled “Medical Device Adverse Events and Advisory Notice Report”, Document #PS-25, Revision 00, dated 3\u002F2\u002F2023, the following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cp>1.&nbsp; The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, there are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803. The exclusion of definitions from 21 CFR 803.3 for the terms “become aware,” “caused or contributed,” “malfunction,” “MDR reportable event,” and “serious injury,” and the definition for the term “reasonably suggests,” found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\n\n\u003Cp>2.&nbsp; Your firm’s procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example:\u003Cbr>\n&nbsp; a.&nbsp; There are no instructions for investigating each MDR reportable event and evaluating the cause of the event.\u003Cbr>\n&nbsp; b.&nbsp; The procedure, as written, does not specify who makes the decision for reporting events to FDA.\u003Cbr>\n&nbsp; c.&nbsp; There are no instructions for how the firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fp>\n\n\u003Cp>3.&nbsp; Your firm’s procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3).Specifically, the following are not addressed:\u003Cbr>\n&nbsp; a.&nbsp; Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>\n&nbsp; b.&nbsp; The circumstances under which the firm must submit initial 30 days, supplemental or follow-up, 5-day report and the requirements for such reports.\u003Cbr>\n&nbsp; c.&nbsp; A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21CFR 803.12(a).\u003Cbr>\n&nbsp; d.&nbsp; How your firm will submit all information reasonably known to it for each event. Specifically, which sections of the 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow up within your firm.\u003C\u002Fp>\n\n\u003Cp>4.&nbsp; Your firm’s procedure does not describe how your firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b), including:\u003Cbr>\n&nbsp; a.&nbsp; Documentation of medical device reports submitted to FDA.\u003Cbr>\n&nbsp; b.&nbsp; Information that was evaluated to determine if an event related to death, serious injury, or malfunction was reportable.\u003Cbr>\n\u003Cbr>\nWe reviewed your firm’s response and concluded that it is not adequate. Your response included a revised MDR procedure titled “Medical Device Adverse Events and Advisory Notice Report”, Document #PS-25, Revision 01, dated 5\u002F15\u002F2023. However, the revision did not address the deficiencies noted above.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. \u003Cstrong>Refer to CMS case # 665754 when replying.\u003C\u002Fstrong> If you have any questions about the contents of this letter, please contact: Stephen Browning at (240) 402-5241 or Stephen.browning@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility.\u003C\u002Fp>\n\n\u003Cp>It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the product into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Bram Zuckerman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT 2: Office of Cardiovascular Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nAmy Orrell\u003Cbr>\nUS Agent\u003C\u002Fp>\n\n\u003Cp>Mazza Healthcare, LLC\u003Cbr>\n2101 Waukegan Rd.\u003Cbr>\nSuite 208\u003Cbr>\nBannockburn, IL US 60015\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nYoshinori Koyama\n\nRecipient Title\n\nPresident Director\n\nP.T. Sankei Medical Industries\n\nJL. Mordern Inustri III, Komp. BPSP A-12\n\nKawasan Industri Modern Cikande\n\nSerang\n\nBanten 42186\n\nIndonesia\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nSeptember 19, 2023\n\nDear Mr. Koyama:\n\nDuring an inspection of your firm located in Banten, Indonesia on May 8, 2023, through May 11, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nWe received a response from you dated May 24, 2023, concerning our investigator(s)’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\n\nUnapproved Device Violations\n\nYou currently have a clearance for the Aneroid Sphygmomanometers\u002FMercurial Sphygmomanometers under K942543. Our inspection revealed that your firm made changes to the materials of the cleared device without submission of a new 510(k). As explained in Section C.4.1 of the guidance document Deciding When to Submit a 510(k) for a Change to an Existing Device1 (“510(k) Modifications Guidance”) in general, changing the material may affect the biocompatibility of the device. Thus, these changes could significantly affect the safety or effectiveness of the device and required the submission of a new 510(k). 21 CFR 807.81(a)(3)(i). Your response did not address this violation.\n\nAccordingly, the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency.21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nQuality System Regulations (QSR) Violations\n\nThis inspection also revealed that this device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nThese violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).For example:\n\nYour Design and Development Procedure (Document #PS-17, Revision 00) is a process for the development of new systems and products as well as existing ones in order to meet external and internal customer requirements. This procedure was not applied to the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device since design controls have not been conducted for the single use sphygmomanometer.\n\nWe reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Design and Development Procedure; however, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide evidence of the corrective actions. For example, this should include documentation and confirmation the design controls were applied to the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device. Please provide all responses and documentation in English or with English translations.\n\n2. Failure to adequately establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21CFR 820.50. For example:\n\nYour Purchasing Procedure (Document #PS-04, Revision 03) requires samples made by potential suppliers to be checked by Quality Assurance (QA). However, this procedure does not detail the specified requirements, including quality requirements, that potential suppliers and contractors must meet. Further, you do not have an agreement with suppliers and\u002For contractors that requires notification of changes in the product to ensure changes do not affect quality of finished devices.\n\nWe reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Purchasing Procedure; however, the new version did not address the deficiencies noted above. Further, the supporting documents provided were not in English and could not be reviewed.\n\nIn response to this Warning Letter, you should provide updated documentation including, but not limited to, an updated Purchasing procedure and documentation of agreements with suppliers and\u002For contractors. You should also provide evidence of the corrective actions. Please provide all responses and documentation in English or with English translations.\n\n3. Failure to adequately ensure Design History Records (DHRs) for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR and the requirements of this part, as required by 21 CFR 820.184 For example:\n\nYour Quality Plan for (b)(4) (Document #QP-DC-0001A, Revision 2) details the required manufacturing steps for the following procedures\u002Fwork instructions including, but not limited to: (b)(4), and (b)(4). However, your firm’s DHRs did not include or refer to the location of the primary identification label and labeling used for each production case. Further, the procedure does not require manufacturing step documentation. Specifically, it does not require technician(s) to document manufacturing\u002Foperation steps in the production record nor utilize any forms to document the manufacturing\u002Foperation steps.\n\nWe reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Quality Plan; however, the new version did not address the deficiencies noted above. Further, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide updated documentation including, but not limited to, updated DHRs for the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device, updates to the DHR procedures and forms. You should also provide evidence of your firm’s corrective actions. Please provide all responses and documentation in English or with English translations.\n\n4. Failure to adequately maintain device master records (DMR's), as required by 21 CFR820.181 For example:\n\nYour Device Master File Procedure (Document #PS-33, Revision 0) requires each DMR to include a Quality Assurance and Reference Documentation section. However, the DMR for the Sphygmomanometer is missing documentation of the Quality Assurance and Reference Document sections. Further, the DMR for the Sphygmomanometer Product has not been reviewed and approved through document controls.\n\nWe reviewed your firm’s response and concluded that it is not adequate. The documents were not provided in English and could not be reviewed. In response to this Warning Letter, you should provide evidence of the corrective actions. For example, this should include updated documentation including, but not limited to, updated DMRs for the Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device. Please provide all responses and documentation in English or with English translations.\n\n5. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198. For example:\n\nYour Customer Claim Handling procedure (Document #PS-15, Revision 01) requires “preventive and corrective actions for the problem must be completed”. However, the procedure does not require review and evaluation of all complaints to determine whether an investigation is necessary, nor does it require the manufacturer to maintain a record that includes the reason no investigation was needed and the name of the individual responsible for the decision not to investigate. Further, it fails to require events meeting the definition of a complaint under 820.3(b) be evaluated to determine whether the complaint represents an event for which reporting is required under 21 CFR part 803, Medical Device Reporting. The procedure states that the Corrective and Preventive Action form is used to document customer claims. The form does not record manufacturer review and evaluation of complaint to determine whether an investigation is necessary.\n\nWe reviewed your firm’s response and concluded that it is not adequate. The response included an updated version of the Customer Claim Handling procedure; however, the new version does not address the deficiencies noted above. Further, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide evidence of updated documentation including, but not limited to, updates to the Customer Claim Handling procedures and forms as well as evidence of the corrective actions. Please provide all responses and documentation in English or with English translations.\n\n6. Failure to establish procedures for quality audits and conduct such audits to assure that the quality system complies with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22. For example:\n\nYour Audit Management System Procedure (Document #PS-02, Revision 03) requires audits to be conducted (b)(4); however, there is no documented evidence to show that the scheduled items\u002Fprocesses of the quality system were audited for 2022 or 2023.\n\nWe reviewed your firm’s response and concluded that it is not adequate. The response included a version of the Audit Management System Procedure; however, the supporting documents provided were not in English and could not be reviewed. In response to this Warning Letter, you should provide an updated documentation including, but not limited to, documentation confirming audit performance and updated Audit Process.\n\nPlease provide all responses and documentation in English or with English translations.\n\nMedical Device Reporting (MDR) Violations\n\nOur inspection also revealed that your firm’s Sphygmomanometer Unit (Adult and Large Adult), Single Use, Latex Free device is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\nFailure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, after reviewing your firm’s MDR procedure titled “Medical Device Adverse Events and Advisory Notice Report”, Document #PS-25, Revision 00, dated 3\u002F2\u002F2023, the following deficiencies were noted:\n\n1. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, there are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803. The exclusion of definitions from 21 CFR 803.3 for the terms “become aware,” “caused or contributed,” “malfunction,” “MDR reportable event,” and “serious injury,” and the definition for the term “reasonably suggests,” found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\n2. Your firm’s procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example:\n\na. There are no instructions for investigating each MDR reportable event and evaluating the cause of the event.\n\nb. The procedure, as written, does not specify who makes the decision for reporting events to FDA.\n\nc. There are no instructions for how the firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\n\n3. Your firm’s procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3).Specifically, the following are not addressed:\n\na. Instructions for how to obtain and complete the FDA 3500A form.\n\nb. The circumstances under which the firm must submit initial 30 days, supplemental or follow-up, 5-day report and the requirements for such reports.\n\nc. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21CFR 803.12(a).\n\nd. How your firm will submit all information reasonably known to it for each event. Specifically, which sections of the 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow up within your firm.\n\n4. Your firm’s procedure does not describe how your firm will address documentation and record-keeping requirements, as required by 21 CFR 803.17(b), including:\n\na. Documentation of medical device reports submitted to FDA.\n\nb. Information that was evaluated to determine if an event related to death, serious injury, or malfunction was reportable.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your response included a revised MDR procedure titled “Medical Device Adverse Events and Advisory Notice Report”, Document #PS-25, Revision 01, dated 5\u002F15\u002F2023. However, the revision did not address the deficiencies noted above.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 665754 when replying. If you have any questions about the contents of this letter, please contact: Stephen Browning at (240) 402-5241 or Stephen.browning@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility.\n\nIt is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the product into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBram Zuckerman, M.D.\n\nDirector\n\nOHT 2: Office of Cardiovascular Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nAmy Orrell\n\nUS Agent\n\nMazza Healthcare, LLC\n\n2101 Waukegan Rd.\n\nSuite 208\n\nBannockburn, IL US 60015","P.T. Sankei Medical Industries","pt-sankei-medical-industries-665754-09192023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpt-sankei-medical-industries-665754-09192023","2026-10-26T08:09:45.256579+00:00","2024-04-30","665754","Yoshinori Koyama","2026-08-20T00:09:33.322+00:00","2023-09-19",{"id":116,"raw":117,"subject":61,"body_html":121,"body_text":122,"firm_name":123,"letter_id":124,"created_at":125,"fei_number":19,"letter_url":126,"updated_at":127,"action_type":22,"case_status":23,"posted_date":128,"marcs_cms_no":129,"product_type":71,"closeout_date":19,"issuing_office":59,"recipient_name":130,"body_fetched_at":131,"delivery_method":74,"recipient_title":19,"reference_number":19,"action_taken_date":128,"medical_device_id":19,"response_letter_date":19},3194,[118,119,120,59,61,13,13,13],"\u003Ctime datetime=\"2021-08-17T19:00:00Z\">08\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-17T04:00:00Z\">08\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftsvl-llc-dba-times-square-vape-lab-616758-08172021\">T.S.V.L. LLC d\u002Fb\u002Fa Times Square Vape Lab\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>James J. Hubbard\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>T.S.V.L. LLC d\u002Fb\u002Fa Times Square Vape Lab\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5201 South Broadway Avenue, Suite 110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tyler\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75703\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Info@tsvapelab.com\"> Info@tsvapelab.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hubbard:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that T.S.V.L. LLC d\u002Fb\u002Fa Times Square Vape Lab manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States TSVL Blue Charm 1.5 mg 60 ml e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 4,000 products listed with FDA. It is your responsibility to ensure that your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address this matter may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100194, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJames J. Hubbard\n\nRecipient Title\n\nOwner\n\nT.S.V.L. LLC d\u002Fb\u002Fa Times Square Vape Lab\n\n5201 South Broadway Avenue, Suite 110\n\nTyler, TX 75703\n\nUnited States\n\nInfo@tsvapelab.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Mr. Hubbard:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that T.S.V.L. LLC d\u002Fb\u002Fa Times Square Vape Lab manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States TSVL Blue Charm 1.5 mg 60 ml e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 4,000 products listed with FDA. It is your responsibility to ensure that your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address this matter may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100194, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","T.S.V.L. LLC d\u002Fb\u002Fa Times Square Vape Lab","tsvl-llc-dba-times-square-vape-lab-616758-08172021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftsvl-llc-dba-times-square-vape-lab-616758-08172021","2026-10-26T08:10:15.759235+00:00","2021-08-17","616758","James J. Hubbard","2026-08-20T02:41:35.302+00:00",{"id":133,"raw":134,"subject":138,"body_html":139,"body_text":140,"firm_name":141,"letter_id":142,"created_at":43,"fei_number":19,"letter_url":143,"updated_at":144,"action_type":22,"case_status":23,"posted_date":145,"marcs_cms_no":146,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":147,"body_fetched_at":148,"delivery_method":149,"recipient_title":19,"reference_number":19,"action_taken_date":150,"medical_device_id":19,"response_letter_date":19},136,[135,136,137,37,138,13,13,13],"\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-20T04:00:00Z\">05\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faversas-italian-bakery-722904-05202026\">Aversa&#039;s Italian Bakery\u003C\u002Fa>","CGMP\u002FHazard Analysis\u002FRisk-Based Preventive Controls for Food\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Rafael Aversa, Sr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aversa's Italian Bakery\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>801 Route 168\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Turnersville\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08012-1472\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:doughboyra@yahoo.com\"> doughboyra@yahoo.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 20, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 722904\u003C\u002Fp>\u003Cp>Dear Mr. Rafael Aversa, Sr.:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection at your food manufacturing facility, Aversa's Italian Bakery, located at 801 Route 168, Turnersville, NJ 08012-1472, between August 11, 2025, and August 19, 2025. During our inspection, the investigator found significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation, Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). In addition, during the inspection, FDA collected finished product samples of steak rolls from your production facility, and the analytical results confirmed the presence of unintended sesame in this product.\u003C\u002Fp>\u003Cp>Based on FDA’s inspectional findings and analytical results for samples collected from your facility, we determined that your ready-to-eat (RTE) bakery products are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in subparts A, B, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 USC § 331(uu)]. A label review was also conducted on your Catering Kaiser, Catering Torpedo, Kaiser Roll, and Steak Roll products which found violations of Food Labeling regulation, Title 21, Code of Federal Regulations, Part 101 (21 CFR Part 101) rendering them to be misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343].\u003C\u002Fp>\u003Cp>You may find the Act and further information about FDA’s regulations through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, FDA issued an FDA Form 483 (FDA-483), Inspectional Observations, listing the violations found at your facility. FDA received your firm’s emailed responses to the FDA-483 on August 27, 2025, and October 24, 2025, describing corrective actions taken by your firm. After reviewing the inspectional findings and your firm’s responses, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility. We also address your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Hazard Analysis and Risk-Based Preventive Controls Requirements (21 CFR Part 117, Subpart C)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. You did not prepare, or have prepared, and implement a food safety plan, as required by 21 CFR § 117.126(a)(1). This is a repeat violation from your previous inspection. The preparation of the food safety plan must be overseen by one or more preventive controls qualified individuals (PCQIs), as required by 21 CFR § 117.126(a)(2), and your food safety plan must include the following:\u003C\u002Fp>\u003Cp>1. The written hazard analysis, as required by 21 CFR § 117.130(a)(2);\u003Cbr>2. The written preventive controls as required by 21 CFR § 117.135(b);\u003Cbr>3. The written supply-chain program, as required by Subpart G;\u003Cbr>4. The written recall plan, as required by 21 CFR § 117.139(a);\u003Cbr>5. The written procedures for monitoring the implementation of the preventive controls, as required by 21 CFR § 117.145(a);\u003Cbr>6. The written corrective action procedures, as required by 21 CFR § 117.150(a)(1); and\u003Cbr>7. The written verification procedures, as required by 21 CFR § 117.165(b).\u003C\u002Fp>\u003Cp>Your facility manufactures a variety of RTE bakery products, including but not limited to Hoagie Rolls with Sesame. However, you did not have a food safety plan with the required elements for any of the products manufactured by your facility. For example, you did not conduct a hazard analysis to identify and evaluate known or reasonably foreseeable hazards for each type of food manufactured, processed, packed, or held at your facility to determine whether there are any hazards requiring a preventive control (see 21 CFR § 117.130(a)). Also, you did not identify and implement preventive controls to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the Act or misbranded under section 403(w) of the Act (see 21 CFR § 117.135(a)(1)). Preventive controls include, as appropriate to the facility and the food, process controls, food allergen controls, sanitation controls, supply-chain controls, and a recall plan (see 21 CFR § 117.135(c)). Preventive controls are subject to preventive control management components (monitoring, verification, and corrective actions) as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility's food safety system (see 21 CFR § 117.140). You must also validate that the preventive controls are adequate to control the hazard as appropriate to the nature of the preventive control and its role in the facility’s food safety system (see 21 CFR § 117.160). Specifically:\u003C\u002Fp>\u003Cp>A. You did not identify and evaluate allergen cross-contact as a known or reasonably foreseeable hazard to determine whether it is a hazard requiring a preventive control, as required under 21 CFR § 130(b)(1)(ii). Your facility manufactures various RTE bakery products that contain allergens (such as wheat, milk, and sesame). Products containing different allergen profiles are processed on shared food-contact surfaces, shared equipment and utensils, on the same production day and with the same employees. Allergens are a known or reasonably foreseeable hazard. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify allergens as a hazard requiring a preventive control. Food allergen controls include procedures, practices, and processes employed for ensuring protection of food from allergen cross-contact (including during storage, handling, and use) and for labeling to ensure that all food allergens required to be stated are included on the label (see 21 CFR § 117.135(c)(2)(i) and (ii)).\u003C\u002Fp>\u003Cp>i. You did not have appropriate controls in place to prevent allergen cross-contact. During the inspection, our investigator observed that you make RTE bread\u002Frolls that contain sesame on shared equipment including wooden boards, conveyor belts, and sorting tables, as bread\u002Frolls that do not contain sesame. You did not sequence, clean, or sanitize between the sesame and non-sesame containing products. Further, on August 12, 2025, our investigator observed the following:\u003Cbr>a. Employees failed to change gloves, wash, or sanitizer their hands between handling sesame containing hoagie rolls and non-sesame containing hoagie rolls at the sorting table.\u003Cbr>b. Sesame containing hoagie rolls and non-sesame containing hoagie rolls were observed on the sorting table at the same time. The non-sesame containing product is not labeled as containing sesame at the finished product \u003Cstrong>(b)(4)\u003C\u002Fstrong> step.\u003Cbr>c. Non-sesame containing dinner rolls packaged in your unlabeled bread boxes contained sesame on the bottom of the roll. This product is not labeled to contain sesame.\u003C\u002Fp>\u003Cp>On August 12, 2025, FDA collected finished product samples of steak rolls from your production facility, and the analytical results confirmed the presence of unintended sesame protein at levels of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm in this product. On October 31, 2025, you confirmed receipt of the sample results relayed to you via email on October 30, 2025.\u003C\u002Fp>\u003Cp>B. You did not identify and evaluate recontamination with environmental pathogens as a known or reasonably foreseeable hazard to determine whether it is a hazard requiring a preventive control to comply with 21 CFR § 117.130(c)(1)(ii). During the inspection, RTE products were observed exposed to the environment during \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the bulk bread boxes. Your firm does not conduct environmental monitoring in areas where RTE breads\u002Frolls are exposed to the environment to verify the adequacy of your firm’s sanitation.\u003C\u002Fp>\u003Cp>C. You did not identify and evaluate physical hazards such as metal as a known or reasonably foreseeable hazard to determine whether it is a hazard requiring a preventive control, as required under 21 CFR § 117.130(b)(1)(iii). During the inspection, our investigator observed that mesh metal was used for forming the raw dough on the dough forming line. The metal mesh was observed to be fraying. Further, raw dough comes into direct contact with the metal mesh and did not go through any type of metal detection.\u003C\u002Fp>\u003Cp>You submitted multiple 483 responses on August 27, 2025, and October 24, 2025. While we acknowledge you submitted three prerequisite programs: an Allergen Management Policy addressing cross-contact through proper storage and dedicated sesame handling procedures, a Sanitary Operations Policy establishing master sanitation schedules and verification protocols, and a Good Manufacturing Practices Policy detailing personnel requirements and visitor controls, you did not provide a complete food safety plan with all elements required by the regulation, despite committing to completing this by October 31, 2025. Additionally, you did not provide evidence to show that your new policies have been implemented.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Current Good Manufacturing Practice (21 CFR Part 117, Subpart B)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. You failed to take reasonable measures or precautions related to personnel practices as required by 21 CFR 117.10(b). This is also a repeat violation from your previous inspection.\u003Cbr>Specifically, on August 11 and 12, 2025, our investigator observed the following:\u003C\u002Fp>\u003Cp>a. Several employees were not wearing hair nets while handling products being packaged.\u003Cbr>b. Employees' personal beverages were observed in production areas.\u003Cbr>c. Several employees were handling raw dough and in-process products while wearing jewelry including earrings and necklaces, as well as wireless headphones.\u003C\u002Fp>\u003Cp>Furthermore, you did not have records available to document that your employees have received food hygiene and food safety training.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranding Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. Your Catering Kaiser and Kaiser Roll products are misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)], in that the finished product label fails to declare a major food allergen (milk). Specifically, your Catering Kaiser and Kaiser Roll products packaged in plastic bags are manufactured with whey, but the label does not list the major food allergen milk. Under section 201(qq) of the Act [21 U.S.C. § 321(qq)], milk is considered a “major food allergen. “A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\u003C\u002Fp>\u003Cul>\u003Cli>The word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. § 343(w)(1)(A)]; or\u003C\u002Fli>\u003Cli>The common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived (e.g., “whey (milk)”), except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. § 343(w)(1)(B)].\u003C\u002Fli>\u003C\u002Ful>\u003Cp>2. Your Catering Kaiser, Catering Torpedo, Kaiser Roll, and Steak Roll products are misbranded within the meaning of section 403(a)(1) of the Act [21 U.S.C. § 343(a)(1)] in that the labeling is false and misleading. Specifically, the net quantity of contents statements is inconsistent with the serving size and servings per container. The same plastic bag label is used for the Catering Kaiser and Catering Torpedo products declared “TOTAL WT. 12 OZ”. Also, the same plastic bag label is used for the Kaiser Roll and Steak Roll products declared “TOTAL WT. 1 LB 5 OZ (21 OZS)”. Based on the Nutrition Facts Label (NFL) serving information:\u003C\u002Fp>\u003Cul>\u003Cli>Catering Kaiser: 12 servings x 57g = 684g (approximately 24 oz)\u003C\u002Fli>\u003Cli>Catering Torpedo: 12 servings x 57g = 684g (approximately 24 oz)\u003C\u002Fli>\u003Cli>Kaiser Roll: 12 servings × 57g = 684g (approximately 24 oz)\u003C\u002Fli>\u003Cli>Steak Roll: 6 servings × 85g = 510g (approximately 17-18 oz)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>For the Catering Kaiser and Catering Torpedo products, the product weight determined from the servings per container and serving size declared in the NFL is inconsistent with the declared weight of 12 OZ. Also, for the Kaiser Roll and Steak Roll products, the product weight determined from the servings per container and serving size declared in the NFL is inconsistent with the declared weight of 1 LB 5 OZ (21 OZS).\u003C\u002Fp>\u003Cp>3. Your Kaiser Roll and Steak Roll products are misbranded within the meaning of section 403(q) of the Act [21 U.S.C. § 343(q)] in that the nutrition information (e.g. Nutrition Facts Label) does not meet the requirements in 21 CFR 101.9. For example, mandatory nutrients such as added sugars, vitamins and minerals such as vitamin D and potassium are not declared as required in 21 CFR 101.9(c), and the footnote is not in accordance with 21 CFR 101.9(d)(9).\u003C\u002Fp>\u003Cp>4. Your Catering Kaiser and Kaiser Roll products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the products are fabricated from two or more ingredients, and the common or usual name of each ingredient is not declared on the label, as required under 21 CFR 101.4. Specifically, during the inspection, our investigator was informed that the same ingredients were used for all your products. The dough formulation includes the ingredient whey, but it is not declared in the ingredient statement for the Catering Kaiser and Kaiser Roll products. According to 21 CFR 101.4(b)(2), the requirement to list these component ingredients (or “subingredients”) may be met by either parenthetically listing the component ingredients after the common or usual name of the main ingredient [21 CFR 101.4(b)(2)(i)], or by listing the component ingredients without listing the ingredient itself [21 CFR 101.4(b)(2)(ii)]. Under the first alternative, the component ingredients must be listed in descending order of predominance within the multi-component ingredient; and under the second alternative, the component ingredients must be listed in descending order of predominance in the finished food.\u003C\u002Fp>\u003Cp>We also note that the Steak Roll and Catering Torpedo products’ ingredient lists are inconsistent with the Kaiser Roll and Catering Kaiser products. Specifically, the Steak Roll and Catering Torpedo products’ ingredient lists do not include the ingredients defatted soy flour and soy lecithin.\u003C\u002Fp>\u003Cp>5. Your Steak Rolls, Kaiser Rolls, Catering Kaiser, and Catering Torpedo products are misbranded within the meaning of Section 403(e)(1) of the Act [21 U.S.C. § 343 (e)(1)] in that they fail to list the place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5(a).\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\u003Cp>In addition to the violations above, we provide the following comments:\u003C\u002Fp>\u003Cul>\u003Cli>You have failed to register your food facility as required by 21 CFR § 1.225 under the Bioterrorism Act and Food Safety Modernization Act. You must complete your facility registration immediately to comply with federal requirements.\u003C\u002Fli>\u003Cli>We note that your firm uses exposed cardboard bread boxes to hold and transport various types of products, including Hoagie Rolls (with and without sesame seeds), Dinner Rolls, and Kaiser Rolls products, which do not include label information, except for the name of the business. During the inspection, you informed our investigator that you would begin placing stickers on the cardboard bread boxes to have an ingredient list and contains statement for allergens, and that you would change the bread boxes at the next printing. We encourage that the information on the bread boxes should be consistent with the information on the retail packages.\u003C\u002Fli>\u003Cli>We note that the Catering Kaiser and Catering Torpedo products share the same label listing both products’ NFL and ingredient list. Similarly, the Kaiser Roll and Steak Roll products also share the same label listing both products’ NFL and ingredient list. The names of the products are located on the information panel. In accordance with 21 CFR 101.3(a), the statement of identity must be on the principal display panel. While the nature of the product is apparent through the clear packaging, we question whether “Catering Kaiser” and “Catering Torpedo” are appropriate statements of identity in accordance with 21 CFR 101.3(b).&nbsp;\u003C\u002Fli>\u003Cli>Your Catering Kaiser, Catering Torpedo, Kaiser Roll, and Steak Roll products are missing the words “Net Weight” in accordance with 21 CFR 101.7(j)(3).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Please notify FDA in writing within fifteen (15) working days of receipt of this letter, of the specific steps and corrections you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply to HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Liza Quiles, Compliance Office, at Liza.Quiles@fda.hhs.gov or by hard copy to the Food and Drug Administration, Attention: Liza Quiles, Compliance Officer Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding this letter, you may contact Liza Quiles, Compliance Officer via email at: Liza.Quiles@fda.hhs.gov. Please reference #722904 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD MBA\u003Cbr>Director\u003Cbr>Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nRafael Aversa, Sr.\n\nRecipient Title\n\nOwner\n\nAversa's Italian Bakery\n\n801 Route 168\n\nTurnersville, NJ 08012-1472\n\nUnited States\n\ndoughboyra@yahoo.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nMay 20, 2026\nWARNING LETTER\nRe: CMS # 722904\nDear Mr. Rafael Aversa, Sr.:\nThe United States Food and Drug Administration (FDA) conducted an inspection at your food manufacturing facility, Aversa's Italian Bakery, located at 801 Route 168, Turnersville, NJ 08012-1472, between August 11, 2025, and August 19, 2025. During our inspection, the investigator found significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation, Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). In addition, during the inspection, FDA collected finished product samples of steak rolls from your production facility, and the analytical results confirmed the presence of unintended sesame in this product.\nBased on FDA’s inspectional findings and analytical results for samples collected from your facility, we determined that your ready-to-eat (RTE) bakery products are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in subparts A, B, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 USC § 331(uu)]. A label review was also conducted on your Catering Kaiser, Catering Torpedo, Kaiser Roll, and Steak Roll products which found violations of Food Labeling regulation, Title 21, Code of Federal Regulations, Part 101 (21 CFR Part 101) rendering them to be misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343].\nYou may find the Act and further information about FDA’s regulations through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\nAt the conclusion of the inspection, FDA issued an FDA Form 483 (FDA-483), Inspectional Observations, listing the violations found at your facility. FDA received your firm’s emailed responses to the FDA-483 on August 27, 2025, and October 24, 2025, describing corrective actions taken by your firm. After reviewing the inspectional findings and your firm’s responses, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility. We also address your responses below.\nHazard Analysis and Risk-Based Preventive Controls Requirements (21 CFR Part 117, Subpart C)\n1. You did not prepare, or have prepared, and implement a food safety plan, as required by 21 CFR § 117.126(a)(1). This is a repeat violation from your previous inspection. The preparation of the food safety plan must be overseen by one or more preventive controls qualified individuals (PCQIs), as required by 21 CFR § 117.126(a)(2), and your food safety plan must include the following:\n1. The written hazard analysis, as required by 21 CFR § 117.130(a)(2);\n2. The written preventive controls as required by 21 CFR § 117.135(b);\n3. The written supply-chain program, as required by Subpart G;\n4. The written recall plan, as required by 21 CFR § 117.139(a);\n5. The written procedures for monitoring the implementation of the preventive controls, as required by 21 CFR § 117.145(a);\n6. The written corrective action procedures, as required by 21 CFR § 117.150(a)(1); and\n7. The written verification procedures, as required by 21 CFR § 117.165(b).\nYour facility manufactures a variety of RTE bakery products, including but not limited to Hoagie Rolls with Sesame. However, you did not have a food safety plan with the required elements for any of the products manufactured by your facility. For example, you did not conduct a hazard analysis to identify and evaluate known or reasonably foreseeable hazards for each type of food manufactured, processed, packed, or held at your facility to determine whether there are any hazards requiring a preventive control (see 21 CFR § 117.130(a)). Also, you did not identify and implement preventive controls to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the Act or misbranded under section 403(w) of the Act (see 21 CFR § 117.135(a)(1)). Preventive controls include, as appropriate to the facility and the food, process controls, food allergen controls, sanitation controls, supply-chain controls, and a recall plan (see 21 CFR § 117.135(c)). Preventive controls are subject to preventive control management components (monitoring, verification, and corrective actions) as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility's food safety system (see 21 CFR § 117.140). You must also validate that the preventive controls are adequate to control the hazard as appropriate to the nature of the preventive control and its role in the facility’s food safety system (see 21 CFR § 117.160). Specifically:\nA. You did not identify and evaluate allergen cross-contact as a known or reasonably foreseeable hazard to determine whether it is a hazard requiring a preventive control, as required under 21 CFR § 130(b)(1)(ii). Your facility manufactures various RTE bakery products that contain allergens (such as wheat, milk, and sesame). Products containing different allergen profiles are processed on shared food-contact surfaces, shared equipment and utensils, on the same production day and with the same employees. Allergens are a known or reasonably foreseeable hazard. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify allergens as a hazard requiring a preventive control. Food allergen controls include procedures, practices, and processes employed for ensuring protection of food from allergen cross-contact (including during storage, handling, and use) and for labeling to ensure that all food allergens required to be stated are included on the label (see 21 CFR § 117.135(c)(2)(i) and (ii)).\ni. You did not have appropriate controls in place to prevent allergen cross-contact. During the inspection, our investigator observed that you make RTE bread\u002Frolls that contain sesame on shared equipment including wooden boards, conveyor belts, and sorting tables, as bread\u002Frolls that do not contain sesame. You did not sequence, clean, or sanitize between the sesame and non-sesame containing products. Further, on August 12, 2025, our investigator observed the following:\na. Employees failed to change gloves, wash, or sanitizer their hands between handling sesame containing hoagie rolls and non-sesame containing hoagie rolls at the sorting table.\nb. Sesame containing hoagie rolls and non-sesame containing hoagie rolls were observed on the sorting table at the same time. The non-sesame containing product is not labeled as containing sesame at the finished product (b)(4) step.\nc. Non-sesame containing dinner rolls packaged in your unlabeled bread boxes contained sesame on the bottom of the roll. This product is not labeled to contain sesame.\nOn August 12, 2025, FDA collected finished product samples of steak rolls from your production facility, and the analytical results confirmed the presence of unintended sesame protein at levels of (b)(4) ppm in this product. On October 31, 2025, you confirmed receipt of the sample results relayed to you via email on October 30, 2025.\nB. You did not identify and evaluate recontamination with environmental pathogens as a known or reasonably foreseeable hazard to determine whether it is a hazard requiring a preventive control to comply with 21 CFR § 117.130(c)(1)(ii). During the inspection, RTE products were observed exposed to the environment during (b)(4) in the bulk bread boxes. Your firm does not conduct environmental monitoring in areas where RTE breads\u002Frolls are exposed to the environment to verify the adequacy of your firm’s sanitation.\nC. You did not identify and evaluate physical hazards such as metal as a known or reasonably foreseeable hazard to determine whether it is a hazard requiring a preventive control, as required under 21 CFR § 117.130(b)(1)(iii). During the inspection, our investigator observed that mesh metal was used for forming the raw dough on the dough forming line. The metal mesh was observed to be fraying. Further, raw dough comes into direct contact with the metal mesh and did not go through any type of metal detection.\nYou submitted multiple 483 responses on August 27, 2025, and October 24, 2025. While we acknowledge you submitted three prerequisite programs: an Allergen Management Policy addressing cross-contact through proper storage and dedicated sesame handling procedures, a Sanitary Operations Policy establishing master sanitation schedules and verification protocols, and a Good Manufacturing Practices Policy detailing personnel requirements and visitor controls, you did not provide a complete food safety plan with all elements required by the regulation, despite committing to completing this by October 31, 2025. Additionally, you did not provide evidence to show that your new policies have been implemented.\nCurrent Good Manufacturing Practice (21 CFR Part 117, Subpart B)\n1. You failed to take reasonable measures or precautions related to personnel practices as required by 21 CFR 117.10(b). This is also a repeat violation from your previous inspection.\nSpecifically, on August 11 and 12, 2025, our investigator observed the following:\na. Several employees were not wearing hair nets while handling products being packaged.\nb. Employees' personal beverages were observed in production areas.\nc. Several employees were handling raw dough and in-process products while wearing jewelry including earrings and necklaces, as well as wireless headphones.\nFurthermore, you did not have records available to document that your employees have received food hygiene and food safety training.\nMisbranding Violations\n1. Your Catering Kaiser and Kaiser Roll products are misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)], in that the finished product label fails to declare a major food allergen (milk). Specifically, your Catering Kaiser and Kaiser Roll products packaged in plastic bags are manufactured with whey, but the label does not list the major food allergen milk. Under section 201(qq) of the Act [21 U.S.C. § 321(qq)], milk is considered a “major food allergen. “A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\nThe word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. § 343(w)(1)(A)]; or\nThe common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived (e.g., “whey (milk)”), except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. § 343(w)(1)(B)].\n2. Your Catering Kaiser, Catering Torpedo, Kaiser Roll, and Steak Roll products are misbranded within the meaning of section 403(a)(1) of the Act [21 U.S.C. § 343(a)(1)] in that the labeling is false and misleading. Specifically, the net quantity of contents statements is inconsistent with the serving size and servings per container. The same plastic bag label is used for the Catering Kaiser and Catering Torpedo products declared “TOTAL WT. 12 OZ”. Also, the same plastic bag label is used for the Kaiser Roll and Steak Roll products declared “TOTAL WT. 1 LB 5 OZ (21 OZS)”. Based on the Nutrition Facts Label (NFL) serving information:\nCatering Kaiser: 12 servings x 57g = 684g (approximately 24 oz)\nCatering Torpedo: 12 servings x 57g = 684g (approximately 24 oz)\nKaiser Roll: 12 servings × 57g = 684g (approximately 24 oz)\nSteak Roll: 6 servings × 85g = 510g (approximately 17-18 oz)\nFor the Catering Kaiser and Catering Torpedo products, the product weight determined from the servings per container and serving size declared in the NFL is inconsistent with the declared weight of 12 OZ. Also, for the Kaiser Roll and Steak Roll products, the product weight determined from the servings per container and serving size declared in the NFL is inconsistent with the declared weight of 1 LB 5 OZ (21 OZS).\n3. Your Kaiser Roll and Steak Roll products are misbranded within the meaning of section 403(q) of the Act [21 U.S.C. § 343(q)] in that the nutrition information (e.g. Nutrition Facts Label) does not meet the requirements in 21 CFR 101.9. For example, mandatory nutrients such as added sugars, vitamins and minerals such as vitamin D and potassium are not declared as required in 21 CFR 101.9(c), and the footnote is not in accordance with 21 CFR 101.9(d)(9).\n4. Your Catering Kaiser and Kaiser Roll products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the products are fabricated from two or more ingredients, and the common or usual name of each ingredient is not declared on the label, as required under 21 CFR 101.4. Specifically, during the inspection, our investigator was informed that the same ingredients were used for all your products. The dough formulation includes the ingredient whey, but it is not declared in the ingredient statement for the Catering Kaiser and Kaiser Roll products. According to 21 CFR 101.4(b)(2), the requirement to list these component ingredients (or “subingredients”) may be met by either parenthetically listing the component ingredients after the common or usual name of the main ingredient [21 CFR 101.4(b)(2)(i)], or by listing the component ingredients without listing the ingredient itself [21 CFR 101.4(b)(2)(ii)]. Under the first alternative, the component ingredients must be listed in descending order of predominance within the multi-component ingredient; and under the second alternative, the component ingredients must be listed in descending order of predominance in the finished food.\nWe also note that the Steak Roll and Catering Torpedo products’ ingredient lists are inconsistent with the Kaiser Roll and Catering Kaiser products. Specifically, the Steak Roll and Catering Torpedo products’ ingredient lists do not include the ingredients defatted soy flour and soy lecithin.\n5. Your Steak Rolls, Kaiser Rolls, Catering Kaiser, and Catering Torpedo products are misbranded within the meaning of Section 403(e)(1) of the Act [21 U.S.C. § 343 (e)(1)] in that they fail to list the place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5(a).\nThe violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\nIn addition to the violations above, we provide the following comments:\nYou have failed to register your food facility as required by 21 CFR § 1.225 under the Bioterrorism Act and Food Safety Modernization Act. You must complete your facility registration immediately to comply with federal requirements.\nWe note that your firm uses exposed cardboard bread boxes to hold and transport various types of products, including Hoagie Rolls (with and without sesame seeds), Dinner Rolls, and Kaiser Rolls products, which do not include label information, except for the name of the business. During the inspection, you informed our investigator that you would begin placing stickers on the cardboard bread boxes to have an ingredient list and contains statement for allergens, and that you would change the bread boxes at the next printing. We encourage that the information on the bread boxes should be consistent with the information on the retail packages.\nWe note that the Catering Kaiser and Catering Torpedo products share the same label listing both products’ NFL and ingredient list. Similarly, the Kaiser Roll and Steak Roll products also share the same label listing both products’ NFL and ingredient list. The names of the products are located on the information panel. In accordance with 21 CFR 101.3(a), the statement of identity must be on the principal display panel. While the nature of the product is apparent through the clear packaging, we question whether “Catering Kaiser” and “Catering Torpedo” are appropriate statements of identity in accordance with 21 CFR 101.3(b).\nYour Catering Kaiser, Catering Torpedo, Kaiser Roll, and Steak Roll products are missing the words “Net Weight” in accordance with 21 CFR 101.7(j)(3).\nPlease notify FDA in writing within fifteen (15) working days of receipt of this letter, of the specific steps and corrections you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nPlease send your reply to HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Liza Quiles, Compliance Office, at Liza.Quiles@fda.hhs.gov or by hard copy to the Food and Drug Administration, Attention: Liza Quiles, Compliance Officer Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding this letter, you may contact Liza Quiles, Compliance Officer via email at: Liza.Quiles@fda.hhs.gov. Please reference #722904 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD MBA\nDirector\nOffice of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Aversa's Italian Bakery","aversas-italian-bakery-722904-05202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faversas-italian-bakery-722904-05202026","2026-10-26T08:07:59.597464+00:00","2026-06-02","722904","Rafael Aversa, Sr.","2026-08-19T04:38:40.52+00:00","VIA Electronic Mail","2026-05-20",{"id":152,"raw":153,"subject":61,"body_html":157,"body_text":158,"firm_name":159,"letter_id":160,"created_at":87,"fei_number":19,"letter_url":161,"updated_at":162,"action_type":22,"case_status":23,"posted_date":163,"marcs_cms_no":164,"product_type":71,"closeout_date":19,"issuing_office":59,"recipient_name":165,"body_fetched_at":166,"delivery_method":74,"recipient_title":19,"reference_number":19,"action_taken_date":167,"medical_device_id":19,"response_letter_date":19},1707,[154,155,156,59,61,13,13,13],"\u003Ctime datetime=\"2023-12-13T14:30:00Z\">12\u002F13\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-12T05:00:00Z\">12\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fs-tacna-inc-dba-vape-mobs-671588-12122023\">A &amp; S Tacna, Inc. d\u002Fb\u002Fa Vape Mobs\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ali Hasan Ali and Stewart J. Namao\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>A &amp; S Tacna, Inc. d\u002Fb\u002Fa Vape Mobs\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>39670 E. Highway 80\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tacna\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85352\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@vapemobs.com\"> support@vapemobs.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 12, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ali Hasan Ali and Stewart J. Namao:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fvapemobs.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. &nbsp;Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R.&nbsp;\u003Cbr>\n§ 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. &nbsp;See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. &nbsp;Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. &nbsp;Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. &nbsp;For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. &nbsp;A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). &nbsp;Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fvapemobs.com revealed that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: Breeze Plus 800 Pineapple Lemon, Elf Bar BC5000 Miami Mint, Funky Republic TI7000 Frozen Edition Watermelon Nana Duo Ice, and Lost Mary OS5000 Blueberry P&amp;B Cloudd.&nbsp;\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. &nbsp;These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. &nbsp;Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). &nbsp;In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. &nbsp;All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States, and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. &nbsp;Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. &nbsp;However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. &nbsp;Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. &nbsp;You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. &nbsp;If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. &nbsp;This letter notifies you of our findings and provides you with an opportunity to address them. &nbsp;You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2302078, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:&nbsp;\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov. &nbsp; &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement&nbsp;\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>VIA Electronic Mail\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nAli Hasan Ali and Stewart J. Namao\n\nA & S Tacna, Inc. d\u002Fb\u002Fa Vape Mobs\n\n39670 E. Highway 80\n\nTacna, AZ 85352\n\nUnited States\n\nsupport@vapemobs.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nDecember 12, 2023\n\nWARNING LETTER\n\nDear Ali Hasan Ali and Stewart J. Namao:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fvapemobs.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R.\n\n§ 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fvapemobs.com revealed that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: Breeze Plus 800 Pineapple Lemon, Elf Bar BC5000 Miami Mint, Funky Republic TI7000 Frozen Edition Watermelon Nana Duo Ice, and Lost Mary OS5000 Blueberry P&B Cloudd.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, these products are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States, and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2302078, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nShopify, Inc.\n\nabuse@shopify.com","A & S Tacna, Inc. d\u002Fb\u002Fa Vape Mobs","s-tacna-inc-dba-vape-mobs-671588-12122023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fs-tacna-inc-dba-vape-mobs-671588-12122023","2026-10-26T08:09:52.196832+00:00","2023-12-13","671588","Ali Hasan Ali and Stewart J. Namao","2026-08-20T00:27:14.658+00:00","2023-12-12",{"id":169,"raw":170,"subject":175,"body_html":177,"body_text":178,"firm_name":179,"letter_id":180,"created_at":66,"fei_number":19,"letter_url":181,"updated_at":182,"action_type":22,"case_status":183,"posted_date":184,"marcs_cms_no":185,"product_type":48,"closeout_date":186,"issuing_office":174,"recipient_name":187,"body_fetched_at":188,"delivery_method":189,"recipient_title":19,"reference_number":19,"action_taken_date":190,"medical_device_id":19,"response_letter_date":19},2957,[171,172,173,174,175,13,176,13],"\u003Ctime datetime=\"2021-12-21T14:20:00Z\">12\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-22T05:00:00Z\">11\u002F22\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaritas-tortilla-factory-inc-617384-11222021\">Sarita&#039;s Tortilla Factory, Inc\u003C\u002Fa>","Office of Human and Animal Food Operations West Division 3","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaritas-tortilla-factory-inc-617384-11302022\">\u003Ctime datetime=\"2022-12-07T05:00:00Z\">12\u002F07\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Maria X. Villarreal\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO and Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sarita's Tortilla Factory, Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2505 El Indio Hwy.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Eagle Pass\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78852-5537\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations West Division 3\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 22, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS #617384\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mrs. Villarreal:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your tortilla manufacturing facility, located at 2505 El Indio Hwy., Eagle Pass, TX 78852-5537 on July 7-12, 2021. This inspection covered your ready-to-eat (RTE) soft flour and corn tortilla manufacturing operation and was conducted as a follow-up to an inspection conducted at your facility on July 30-31, 2019. Both inspections revealed serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule) in \u003Cem>Title 21, Code of Regulations\u003C\u002Fem>, Part 117 (21 CFR part 117). At the conclusion of the inspection, FDA issued a Form FDA 483, Inspectional Observations, listing deviations found at your firm.\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings, we have determined that the RTE tortilla products manufactured in your facility are adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 \u003Cem>United States Code\u003C\u002Fem> (U.S.C.) § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by Section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP &amp; PC rule through links in FDA's Internet home page at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>FDA’s inspection on July 7-12, 2021, resulted in the issuance of a Form FDA 483, Inspectional Observations (FDA 483), listing deviations found during our inspection. We received your responses via email on July 26, 2021, which included a cleaning schedule, cleaning log, and recall protocol. After reviewing the inspectional findings and your response to the observations listed in the FDA 483, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls (21 CFR part 117, Subpart C):\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. You did not prepare, or have prepared, and implement a food safety plan as required by 21 CFR § 117.126(a)(1). The preparation of the food safety plan must be overseen by your preventive controls qualified individual (PCQI) and must include the following:\u003C\u002Fp>\n\n\u003Cp>(1) A written hazard analysis, as required by 21 CFR § 117.130(a)(2);\u003Cbr>\n(2) Written preventive controls, as required by 21 CFR § 117.135(b);\u003Cbr>\n(3) A written supply-chain program, as required by Subpart G;\u003Cbr>\n(4) A written recall plan, as required by 21 CFR § 117.139(a);\u003Cbr>\n(5) Written procedures for monitoring the implementation of the preventive controls, as required by 21 CFR § 117.145(a);\u003Cbr>\n(6) Written corrective action procedures, as required by 21 CFR § 117.150(a)(1); and\u003Cbr>\n(7) Written verification procedures, as required by 21 CFR § 117.165(b).\u003C\u002Fp>\n\n\u003Cp>2. You did not conduct a hazard analysis for each type of food manufactured, processed, packed, or held at your facility to identify and evaluate known or reasonably foreseeable hazards to determine whether there are any hazards requiring a preventive control, as required by 21 CFR § 117.130(a). Specifically:\u003C\u002Fp>\n\n\u003Cp>a. You did not identify and evaluate allergens as a known or reasonably foreseeable hazard to determine whether allergens are a hazard requiring a preventive control. Your facility manufactures soft flour tortillas (which contain allergens including wheat and whey (milk)) and soft corn tortillas (which do not contain allergens) in the same production area, using shared utensils.\u003C\u002Fp>\n\n\u003Cp>b. You did not identify and evaluate environmental pathogens, such as \u003Cem>Salmonella\u003C\u002Fem>, as a known or reasonably foreseeable hazard to determine whether they are a hazard requiring a preventive control, to comply with 21 CFR § 117.130(c)(1)(ii). Your facility manufactures RTE soft flour and corn tortillas which are exposed to the environment after they exit their respective ovens and are cooled on the cooling conveyors prior to packaging. The packaged food does not receive any further lethal treatment or otherwise include a control measure (such as a formulation lethal to the pathogen that would significantly minimize the pathogen). Note that environmental monitoring is required if contamination of an RTE food with an environmental pathogen is a hazard requiring a preventive control (see 21 CFR § 117.165(a)(3)).\u003C\u002Fp>\n\n\u003Cp>c. You did not identify and evaluate mycotoxins as a known or reasonably foreseeable hazard to determine whether they are a hazard requiring a preventive control. Your facility manufactures soft flour and corn tortillas using wheat flour and corn flour. These ingredients have been associated with mycotoxins such as deoxynivalenol (DON) and aflatoxin, respectively.\u003C\u002Fp>\n\n\u003Cp>3. You did not identify and implement preventive controls to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the food manufactured, processed, packed, or held by your facility will not be adulterated under Section 402 of the Act or misbranded under Section 403(w) of the Act, as required by 21 CFR § 117.135(a)(1). Preventive controls include, as appropriate to the facility and the food, process controls, food allergen controls, sanitation controls, supply-chain controls, and a recall plan (see 21 CFR § 117.135). Preventive controls are subject to preventive control management components as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility's food safety system (see 21 CFR § 117.140).\u003C\u002Fp>\n\n\u003Cp>For example, food allergen controls include procedures, practices, and processes employed for labeling to ensure that all food allergens are included on the label and that food is protected against allergen cross-contact (see 21 CFR 117.135(c)(2)). You do not have controls in place to adequately control the hazard of allergen cross-contact as evidenced by the following. Production employees were observed using a metal can as a measuring cup to measure and dispense allergenic (whey) and non-allergenic ingredients during the production of both flour and corn tortillas with no cleaning of the can in-between. Additionally, on July 7, 2021, the metal can exhibited a caked-on reside from various dry ingredients from the flour tortilla production and was then used on the corn tortilla production line without cleaning prior to use. Further, you do not have controls in place to adequately control the hazard of undeclared allergens due to incorrect labeling, as evidenced by the following. Your facility manufactures soft flour tortillas that contain allergens such as wheat and whey (milk). Production employees were observed packaging tortillas but there was no evidence of checks that correctly labeled bags were used.\u003C\u002Fp>\n\n\u003Cp>Your written FDA 483 response dated July 26, 2021, included copies of your facility’s recall procedure, cleaning schedule, and an in-use cleaning schedule log. However, you did not provide information as to how these documents apply to preparing and implementing a food safety plan. You did not include in your response information concerning developing a food safety plan to include evaluating whether hazards require a preventive control and written preventive controls. In the response, your PCQI stated that they would be sending a response to the FDA 483 observations in a later email. However, no additional response has been received.\u003C\u002Fp>\n\n\u003Cp>This is a repeat observation from the July 30-31, 2019, FDA inspection, during which time you stated that you would conduct a hazard analysis and create a food safety plan.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Current Good Manufacturing Practice (21 CFR part 117, Subpart B):\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>4. You did not maintain buildings, fixtures, and other physical facilities of your plant in a clean and sanitary condition and in repair adequate to prevent food from becoming adulterated, as required by 21 CFR § 117.35(a). Specifically, FDA investigators observed the following:\u003C\u002Fp>\n\n\u003Cp>a. Water was dripping from a ceiling with peeling paint onto a pallet of \u003Cstrong>(b)(4)\u003C\u002Fstrong>-\u003Cstrong>(b)(4)\u003C\u002Fstrong> bags of flour.\u003Cbr>\nb. Filth was present on metal air vents and fans located directly above RTE soft flour and corn tortillas. The fans are used to cool the tortillas after cooking.\u003C\u002Fp>\n\n\u003Cp>5. You did not ensure that your cleaning compounds and sanitizing agents are safe and adequate under the conditions of use, as required by 21 CFR § 117.35(b)(1). Specifically, during the inspection, FDA investigators observed the following:\u003C\u002Fp>\n\n\u003Cp>a. Employees were not monitoring sanitizer solutions and were using \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitizer at a concentration of less than the manufacturer’s recommendation \u003Cstrong>(b)(4)\u003C\u002Fstrong> on a food contact surface. Specifically, when an FDA investigator tested with test strips \u003Cstrong>(b)(4)\u003C\u002Fstrong> solutions that were intended to sanitize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> mixer, the concentration was found below 10 ppm and 100 ppm for the two solutions.\u003Cbr>\nb. Employees did not allow the sanitizers to adequately air-dry after being sprayed onto food-contact surfaces, as directed by the manufacturer’s directions. Your PCQI explained that you do not allow the sanitizer to air dry, instead your firm wipes off the sanitizer after it has been applied.\u003C\u002Fp>\n\n\u003Cp>6. You did not identify sanitizing agents in a manner that protects against contamination, as required by 21 CFR § 117.35(b)(2). Specifically, unlabeled containers\u002Fbottles containing unknown substances were observed being used on the tortilla oven conveyor belts, which are food-contact surfaces. According to your PCQI, some containers\u002Fbottles contained non-stick agents, and others contained sanitizer solutions.\u003Cbr>\n\u003Cbr>\n7. You did not take effective measure to exclude pests from your food plant to protect against contamination of food, as required by 21 CFR § 117.35(c). Specifically, on July 7, 2021, FDA investigators observed the following:\u003C\u002Fp>\n\n\u003Cp>a. Several live insects were crawling and flying inside the production room.\u003Cbr>\nb. A live frog was inside the raw ingredients room, under a pallet of wheat flour. The frog was observed to enter the facility through a gap in the loading bay door.\u003Cbr>\nc. An unscreened door was open at the north side of the facility during the production of soft flour and corn tortillas.\u003Cbr>\nd. There were gaps along two screened doors located in your facility’s loading areas on the northeast side and west side of the building.\u003C\u002Fp>\n\n\u003Cp>8. You did not conduct operations under conditions and controls necessary to minimize the potential for contamination of food, as required by 21 CFR § 117.80(c)(2). Specifically, during the inspection, FDA investigators observed:\u003C\u002Fp>\n\n\u003Cp>a. Production employees inserted an approximately 12-inch piece of splinted wood into corn tortilla dough prior to the corn tortilla dough being placed into the pressing machine and manufactured into soft corn tortillas. In addition, another piece of wood with red residue was observed in a nearby tool\u002Fequipment box. An employee explained that this piece of wood was used on July 7, 2021, for red corn tortilla dough.\u003Cbr>\nb. Production employees used non-food-grade grease on tortilla production equipment, specifically on metal parts located directly above uncooked tortillas. The label states that the grease is intended for vehicle parts.\u003C\u002Fp>\n\n\u003Cp>Your written FDA 483 response did not specifically address these FDA 483 observations; therefore, we are unable to evaluate whether you have corrected these deviations.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing the recurrence of occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address the violations noted in this letter. Failure to promptly address these violations may result in legal action without further notice, including seizure and injunction or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within 15 working days of receipt of this letter, of the specific steps you have taken to address violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the time frame within which you will do so.\u003C\u002Fp>\n\n\u003Cp>Section 743 of the FDCA (21 U.S.C. 379j-31) authorizes FDA to assess and collect fees to cover FDA's costs for certain activities, including re-inspection-related costs. A re-inspection is one or more inspections conducted subsequent to an inspection that identified noncompliance materially related to a food safety requirement of the Act, specifically to determine whether compliance has been achieved. Re-inspection-related costs means all expenses, including administrative expenses, incurred in connection with FDA's arranging, conducting, and evaluating the results of the re-inspection, assessing and collecting the re-inspection fees [21 U.S.C. 379j-31(a)(2)(B)]. For a domestic facility, FDA will assess and collect fees for re-inspection-related costs from the responsible party for the domestic facility.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to Rene R. Ramirez, Compliance Officer, U.S. Food and Drug Administration, 1201 North Main Street, Suite 7200, Dallas, TX 75202. If you have questions regarding any issues in this letter, please contact Mr. Ramirez at rene.ramirez@fda.hhs.gov or (210) 308-1425.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Edmundo Garcia, Jr.\u003Cbr>\nProgram Division Director HAF West 3\u003Cbr>\nDallas District Director\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>Texas Department of State Health Services\u003Cbr>\nLori Woznicki, M.P.H.\u003Cbr>\nFood and Drug Inspections Branch Manager\u003Cbr>\n1100 West 49th Street\u003Cbr>\nAustin, TX 78756\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMaria X. Villarreal\n\nRecipient Title\n\nCEO and Co-Owner\n\nSarita's Tortilla Factory, Inc\n\n2505 El Indio Hwy.\n\nEagle Pass, TX 78852-5537\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations West Division 3\n\nUnited States\n\nNovember 22, 2021\n\nWARNING LETTER\n\nCMS #617384\n\nDear Mrs. Villarreal:\n\nThe U.S. Food and Drug Administration (FDA) inspected your tortilla manufacturing facility, located at 2505 El Indio Hwy., Eagle Pass, TX 78852-5537 on July 7-12, 2021. This inspection covered your ready-to-eat (RTE) soft flour and corn tortilla manufacturing operation and was conducted as a follow-up to an inspection conducted at your facility on July 30-31, 2019. Both inspections revealed serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule) in Title 21, Code of Regulations, Part 117 (21 CFR part 117). At the conclusion of the inspection, FDA issued a Form FDA 483, Inspectional Observations, listing deviations found at your firm.\n\nBased on FDA’s inspectional findings, we have determined that the RTE tortilla products manufactured in your facility are adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 United States Code (U.S.C.) § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by Section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP & PC rule through links in FDA's Internet home page at http:\u002F\u002Fwww.fda.gov.\n\nFDA’s inspection on July 7-12, 2021, resulted in the issuance of a Form FDA 483, Inspectional Observations (FDA 483), listing deviations found during our inspection. We received your responses via email on July 26, 2021, which included a cleaning schedule, cleaning log, and recall protocol. After reviewing the inspectional findings and your response to the observations listed in the FDA 483, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility.\n\nHazard Analysis and Risk-Based Preventive Controls (21 CFR part 117, Subpart C):\n\n1. You did not prepare, or have prepared, and implement a food safety plan as required by 21 CFR § 117.126(a)(1). The preparation of the food safety plan must be overseen by your preventive controls qualified individual (PCQI) and must include the following:\n\n(1) A written hazard analysis, as required by 21 CFR § 117.130(a)(2);\n\n(2) Written preventive controls, as required by 21 CFR § 117.135(b);\n\n(3) A written supply-chain program, as required by Subpart G;\n\n(4) A written recall plan, as required by 21 CFR § 117.139(a);\n\n(5) Written procedures for monitoring the implementation of the preventive controls, as required by 21 CFR § 117.145(a);\n\n(6) Written corrective action procedures, as required by 21 CFR § 117.150(a)(1); and\n\n(7) Written verification procedures, as required by 21 CFR § 117.165(b).\n\n2. You did not conduct a hazard analysis for each type of food manufactured, processed, packed, or held at your facility to identify and evaluate known or reasonably foreseeable hazards to determine whether there are any hazards requiring a preventive control, as required by 21 CFR § 117.130(a). Specifically:\n\na. You did not identify and evaluate allergens as a known or reasonably foreseeable hazard to determine whether allergens are a hazard requiring a preventive control. Your facility manufactures soft flour tortillas (which contain allergens including wheat and whey (milk)) and soft corn tortillas (which do not contain allergens) in the same production area, using shared utensils.\n\nb. You did not identify and evaluate environmental pathogens, such as Salmonella, as a known or reasonably foreseeable hazard to determine whether they are a hazard requiring a preventive control, to comply with 21 CFR § 117.130(c)(1)(ii). Your facility manufactures RTE soft flour and corn tortillas which are exposed to the environment after they exit their respective ovens and are cooled on the cooling conveyors prior to packaging. The packaged food does not receive any further lethal treatment or otherwise include a control measure (such as a formulation lethal to the pathogen that would significantly minimize the pathogen). Note that environmental monitoring is required if contamination of an RTE food with an environmental pathogen is a hazard requiring a preventive control (see 21 CFR § 117.165(a)(3)).\n\nc. You did not identify and evaluate mycotoxins as a known or reasonably foreseeable hazard to determine whether they are a hazard requiring a preventive control. Your facility manufactures soft flour and corn tortillas using wheat flour and corn flour. These ingredients have been associated with mycotoxins such as deoxynivalenol (DON) and aflatoxin, respectively.\n\n3. You did not identify and implement preventive controls to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the food manufactured, processed, packed, or held by your facility will not be adulterated under Section 402 of the Act or misbranded under Section 403(w) of the Act, as required by 21 CFR § 117.135(a)(1). Preventive controls include, as appropriate to the facility and the food, process controls, food allergen controls, sanitation controls, supply-chain controls, and a recall plan (see 21 CFR § 117.135). Preventive controls are subject to preventive control management components as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility's food safety system (see 21 CFR § 117.140).\n\nFor example, food allergen controls include procedures, practices, and processes employed for labeling to ensure that all food allergens are included on the label and that food is protected against allergen cross-contact (see 21 CFR 117.135(c)(2)). You do not have controls in place to adequately control the hazard of allergen cross-contact as evidenced by the following. Production employees were observed using a metal can as a measuring cup to measure and dispense allergenic (whey) and non-allergenic ingredients during the production of both flour and corn tortillas with no cleaning of the can in-between. Additionally, on July 7, 2021, the metal can exhibited a caked-on reside from various dry ingredients from the flour tortilla production and was then used on the corn tortilla production line without cleaning prior to use. Further, you do not have controls in place to adequately control the hazard of undeclared allergens due to incorrect labeling, as evidenced by the following. Your facility manufactures soft flour tortillas that contain allergens such as wheat and whey (milk). Production employees were observed packaging tortillas but there was no evidence of checks that correctly labeled bags were used.\n\nYour written FDA 483 response dated July 26, 2021, included copies of your facility’s recall procedure, cleaning schedule, and an in-use cleaning schedule log. However, you did not provide information as to how these documents apply to preparing and implementing a food safety plan. You did not include in your response information concerning developing a food safety plan to include evaluating whether hazards require a preventive control and written preventive controls. In the response, your PCQI stated that they would be sending a response to the FDA 483 observations in a later email. However, no additional response has been received.\n\nThis is a repeat observation from the July 30-31, 2019, FDA inspection, during which time you stated that you would conduct a hazard analysis and create a food safety plan.\n\nCurrent Good Manufacturing Practice (21 CFR part 117, Subpart B):\n\n4. You did not maintain buildings, fixtures, and other physical facilities of your plant in a clean and sanitary condition and in repair adequate to prevent food from becoming adulterated, as required by 21 CFR § 117.35(a). Specifically, FDA investigators observed the following:\n\na. Water was dripping from a ceiling with peeling paint onto a pallet of (b)(4)-(b)(4) bags of flour.\n\nb. Filth was present on metal air vents and fans located directly above RTE soft flour and corn tortillas. The fans are used to cool the tortillas after cooking.\n\n5. You did not ensure that your cleaning compounds and sanitizing agents are safe and adequate under the conditions of use, as required by 21 CFR § 117.35(b)(1). Specifically, during the inspection, FDA investigators observed the following:\n\na. Employees were not monitoring sanitizer solutions and were using (b)(4) sanitizer at a concentration of less than the manufacturer’s recommendation (b)(4) on a food contact surface. Specifically, when an FDA investigator tested with test strips (b)(4) solutions that were intended to sanitize the (b)(4) mixer, the concentration was found below 10 ppm and 100 ppm for the two solutions.\n\nb. Employees did not allow the sanitizers to adequately air-dry after being sprayed onto food-contact surfaces, as directed by the manufacturer’s directions. Your PCQI explained that you do not allow the sanitizer to air dry, instead your firm wipes off the sanitizer after it has been applied.\n\n6. You did not identify sanitizing agents in a manner that protects against contamination, as required by 21 CFR § 117.35(b)(2). Specifically, unlabeled containers\u002Fbottles containing unknown substances were observed being used on the tortilla oven conveyor belts, which are food-contact surfaces. According to your PCQI, some containers\u002Fbottles contained non-stick agents, and others contained sanitizer solutions.\n\n7. You did not take effective measure to exclude pests from your food plant to protect against contamination of food, as required by 21 CFR § 117.35(c). Specifically, on July 7, 2021, FDA investigators observed the following:\n\na. Several live insects were crawling and flying inside the production room.\n\nb. A live frog was inside the raw ingredients room, under a pallet of wheat flour. The frog was observed to enter the facility through a gap in the loading bay door.\n\nc. An unscreened door was open at the north side of the facility during the production of soft flour and corn tortillas.\n\nd. There were gaps along two screened doors located in your facility’s loading areas on the northeast side and west side of the building.\n\n8. You did not conduct operations under conditions and controls necessary to minimize the potential for contamination of food, as required by 21 CFR § 117.80(c)(2). Specifically, during the inspection, FDA investigators observed:\n\na. Production employees inserted an approximately 12-inch piece of splinted wood into corn tortilla dough prior to the corn tortilla dough being placed into the pressing machine and manufactured into soft corn tortillas. In addition, another piece of wood with red residue was observed in a nearby tool\u002Fequipment box. An employee explained that this piece of wood was used on July 7, 2021, for red corn tortilla dough.\n\nb. Production employees used non-food-grade grease on tortilla production equipment, specifically on metal parts located directly above uncooked tortillas. The label states that the grease is intended for vehicle parts.\n\nYour written FDA 483 response did not specifically address these FDA 483 observations; therefore, we are unable to evaluate whether you have corrected these deviations.\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing the recurrence of occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address the violations noted in this letter. Failure to promptly address these violations may result in legal action without further notice, including seizure and injunction or administrative action for suspension of food facility registration if criteria and conditions warrant.\n\nPlease notify this office in writing within 15 working days of receipt of this letter, of the specific steps you have taken to address violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the time frame within which you will do so.\n\nSection 743 of the FDCA (21 U.S.C. 379j-31) authorizes FDA to assess and collect fees to cover FDA's costs for certain activities, including re-inspection-related costs. A re-inspection is one or more inspections conducted subsequent to an inspection that identified noncompliance materially related to a food safety requirement of the Act, specifically to determine whether compliance has been achieved. Re-inspection-related costs means all expenses, including administrative expenses, incurred in connection with FDA's arranging, conducting, and evaluating the results of the re-inspection, assessing and collecting the re-inspection fees [21 U.S.C. 379j-31(a)(2)(B)]. For a domestic facility, FDA will assess and collect fees for re-inspection-related costs from the responsible party for the domestic facility.\n\nYour written response should be sent to Rene R. Ramirez, Compliance Officer, U.S. Food and Drug Administration, 1201 North Main Street, Suite 7200, Dallas, TX 75202. If you have questions regarding any issues in this letter, please contact Mr. Ramirez at rene.ramirez@fda.hhs.gov or (210) 308-1425.\n\nSincerely,\n\n\u002FS\u002F\n\nEdmundo Garcia, Jr.\n\nProgram Division Director HAF West 3\n\nDallas District Director\n\nCc:\n\nTexas Department of State Health Services\n\nLori Woznicki, M.P.H.\n\nFood and Drug Inspections Branch Manager\n\n1100 West 49th Street\n\nAustin, TX 78756","Sarita's Tortilla Factory, Inc","saritas-tortilla-factory-inc-617384-11222021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaritas-tortilla-factory-inc-617384-11222021","2026-10-26T08:09:54.042329+00:00","Closed Out","2021-12-21","617384","2022-12-07","Maria X. Villarreal","2026-08-20T02:19:13.505+00:00","UPS","2021-11-22",{"id":192,"raw":193,"subject":61,"body_html":196,"body_text":197,"firm_name":198,"letter_id":199,"created_at":200,"fei_number":19,"letter_url":201,"updated_at":202,"action_type":22,"case_status":23,"posted_date":203,"marcs_cms_no":204,"product_type":71,"closeout_date":19,"issuing_office":59,"recipient_name":19,"body_fetched_at":205,"delivery_method":74,"recipient_title":19,"reference_number":206,"action_taken_date":203,"medical_device_id":19,"response_letter_date":19},671,[194,194,195,59,61,13,13,13],"\u003Ctime datetime=\"2025-09-11T04:00:00Z\">09\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwild-bills-tobacco-alpena-llc-712517-09112025\">Wild Bill&#039;s Tobacco of Alpena LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501263\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Wild Bill's Tobacco of Alpena LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1037 North Bagley Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alpena\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>49707\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 11, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Wild Bill's Tobacco of Alpena LLC sells and\u002For distributes electronic nicotine delivery system (ENDS) products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States the following ENDS products that lack a marketing authorization order: Geek Bar Pulse X Blackberry Blueberry 50MG\u002FML Nicotine.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501263, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501263\n\nProduct:\n\nTobacco\n\nRecipient:\n\nWild Bill's Tobacco of Alpena LLC\n\n1037 North Bagley Street\n\nAlpena, MI 49707\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSeptember 11, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Wild Bill's Tobacco of Alpena LLC sells and\u002For distributes electronic nicotine delivery system (ENDS) products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States the following ENDS products that lack a marketing authorization order: Geek Bar Pulse X Blackberry Blueberry 50MG\u002FML Nicotine.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501263, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","Wild Bill's Tobacco of Alpena LLC","wild-bills-tobacco-alpena-llc-712517-09112025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwild-bills-tobacco-alpena-llc-712517-09112025","2026-10-26T08:10:32.024838+00:00","2025-09-11","712517","2026-08-19T16:26:07.336+00:00","ER2501263",{"id":208,"raw":209,"subject":61,"body_html":213,"body_text":214,"firm_name":215,"letter_id":216,"created_at":66,"fei_number":19,"letter_url":217,"updated_at":218,"action_type":22,"case_status":23,"posted_date":219,"marcs_cms_no":220,"product_type":71,"closeout_date":19,"issuing_office":59,"recipient_name":221,"body_fetched_at":222,"delivery_method":74,"recipient_title":19,"reference_number":19,"action_taken_date":219,"medical_device_id":19,"response_letter_date":19},2697,[210,211,212,59,61,13,13,13],"\u003Ctime datetime=\"2022-05-03T19:00:00Z\">05\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-03T04:00:00Z\">05\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flyndas-legacy-llc-dba-chaneys-tobacco-station-631769-05032022\">Lynda’s Legacy LLC d\u002Fb\u002Fa Chaney’s Tobacco Station\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Chad Chaney\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lynda’s Legacy LLC d\u002Fb\u002Fa Chaney’s Tobacco Station\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>701 West Moore Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Terrell\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75160\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:chad@chaneystores.com\"> chad@chaneystores.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 3, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chaney:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Lynda’s Legacy LLC d\u002Fb\u002Fa Chaney’s Tobacco Station manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Chaney’s Vape Station Marbo 1.8% Nicotine 120 ml e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 3,100 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003Cbr>\nPage 3 – Lynda’s Legacy LLC d\u002Fb\u002Fa Chaney’s Tobacco Station\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200530, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nChad Chaney\n\nRecipient Title\n\nOwner\n\nLynda’s Legacy LLC d\u002Fb\u002Fa Chaney’s Tobacco Station\n\n701 West Moore Avenue\n\nTerrell, TX 75160\n\nUnited States\n\nchad@chaneystores.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMay 3, 2022\n\nWARNING LETTER\n\nDear Mr. Chaney:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Lynda’s Legacy LLC d\u002Fb\u002Fa Chaney’s Tobacco Station manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Chaney’s Vape Station Marbo 1.8% Nicotine 120 ml e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 3,100 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPage 3 – Lynda’s Legacy LLC d\u002Fb\u002Fa Chaney’s Tobacco Station\n\nPlease note your reference number, ER2200530, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Lynda’s Legacy LLC d\u002Fb\u002Fa Chaney’s Tobacco Station","lyndas-legacy-llc-dba-chaneys-tobacco-station-631769-05032022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flyndas-legacy-llc-dba-chaneys-tobacco-station-631769-05032022","2026-10-26T08:09:17.584539+00:00","2022-05-03","631769","Chad Chaney","2026-08-20T01:57:28.054+00:00",{"id":224,"raw":225,"subject":230,"body_html":231,"body_text":232,"firm_name":233,"letter_id":234,"created_at":200,"fei_number":19,"letter_url":235,"updated_at":236,"action_type":22,"case_status":23,"posted_date":237,"marcs_cms_no":238,"product_type":239,"closeout_date":19,"issuing_office":229,"recipient_name":240,"body_fetched_at":241,"delivery_method":95,"recipient_title":19,"reference_number":242,"action_taken_date":243,"medical_device_id":19,"response_letter_date":19},686,[226,227,228,229,230,13,13,13],"\u003Ctime datetime=\"2025-09-02T04:00:00Z\">09\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-20T04:00:00Z\">08\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchromatography-institute-america-dba-compounders-international-analytical-laboratory-708944-08202025\">Chromatography Institute of America dba Compounder’s International Analytical Laboratory \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceutical\u002FAPI\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-101\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ronald E. Sutton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Chromatography Institute of America dba Compounder’s International Analytical Laboratory \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4760 Castleton Way, Suite A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Castle Rock\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80109\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rsutton@compounderslab.com\"> rsutton@compounderslab.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-101\u003C\u002Fp>\u003Cp>August 20, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Sutton:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your contract testing laboratory, Chromatography Institute of America dba Compounder’s International Analytical Laboratory, FEI 3012069146, at 4760 Castleton Way, Suite A, Castle Rock, Colorado, from February 24 to March 5, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) requirements for finished pharmaceuticals and significant deviations from CGMP for active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drugs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your March 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations and deviations including but not limited to the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Lack of adequate laboratory control mechanisms\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm conducts chemical and microbiological testing of APIs, drug products compounded by outsourcing facilities registered under section 503B of the FD&amp;C Act, and finished drug products for human and animal use. Records and information collected during the inspection demonstrate that you use the same methods and procedures whether you are testing APIs, drug products compounded by outsourcing facilities registered under section 503B of the FD&amp;C Act, or finished drug products for human and animal use.\u003C\u002Fp>\u003Cp>You lacked adequate controls to ensure the reliability of your microbiological testing results. For example, you documented sterility failures for several samples prepared in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> media lot, but you were unable to show that you performed growth promotion testing on this lot before use. In your investigations into these sterility failures, you noted “false positives” with this lot, but you did not include appropriate negative controls corresponding to this lot in your tests and lacked sufficient evidence to support your “false positives” statement. Moreover, after obtaining a failing sterility test result, you repeated the test on a fraction of the original sample amount, which is not in accordance with USP &lt;71&gt; and is an unacceptable practice.\u003C\u002Fp>\u003Cp>In your response, you state that you rely on your manufacturer’s certificates of analysis to establish media suitability. You indicate that you perform growth promotion testing \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that moving forward, you commit to performing growth promotion testing on \u003Cstrong>(b)(4)\u003C\u002Fstrong> media lot. Additionally, you assert that you will revise your procedures to note that you will perform retesting of a failed sample, provided that sufficient sample quantity remains after initial testing. You also assert that you follow all aspects of USP &lt;71&gt; “as best as is possible.”\u003C\u002Fp>\u003Cp>Your response is inadequate because you did not include a comparability analysis of your sterility test method and USP &lt;71&gt; method, to show that your method is equivalent despite the deviations from USP &lt;71&gt; requirements, such as growth promotion testing, negative controls, and sterility retest sample amounts. You also did not include any documentary evidence to support your assertions about random testing and updated procedures.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to evaluate and remediate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan for your sterility testing procedure to ensure that it satisfies all requirements specified in USP &lt;71&gt;. Include:\u003Cbr>o Instructions for how you determine which of your method kits (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) purchased from third-party suppliers are suitable for sterility testing of your laboratory samples.\u003Cbr>o A requirement that each media lot used in the preparation of sterility samples on a given day will include an appropriate negative control.\u003Cbr>o Requirements for appropriate sample amounts needed for a sterility retest.\u003C\u002Fli>\u003Cli>A remediation plan for qualification of your suppliers of growth media. Include a commitment to perform growth promotion testing on all incoming media lots used for microbial and sterility testing, to verify their suitability for use.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Lack of adequate investigations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your investigations into multiple failed sterility test results were inadequate. In 2024, you had nine drug product sterility test failures, for which your investigation concluded that the probable root cause was “technician error – environmental contamination.” However, your root cause was not supported by the environmental monitoring data on the dates when the failing sterility samples were prepared. You did not recover any microorganisms on settle plates from your ISO 7 sterility suite, on ISO 5 “compounding aseptic isolators” where your sterility samples are prepared, or on contact plates used for monitoring of personnel who prepared the sterility samples. You subsequently performed a new analysis on the drug product samples, and you recorded the passing results.\u003C\u002Fp>\u003Cp>In your response, you indicate that you initiated corrective and preventive actions (CAPA), which included the retraining of technicians and their dismissal upon repeated infractions, review of your sterility procedures and cleaning agents, and the frequency of cleaning the sterility suite.\u003C\u002Fp>\u003Cp>Your response is inadequate. You initially identified the potential root cause “technician error – environmental contamination” in 2024, and you continued to note this root cause in several subsequent sterility out-of-specification (OOS) investigations, without identifying and implementing the appropriate CAPA from these investigations to prevent similar future errors.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products for the last three years from the initial date of inspection, and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and the evidence relating to the invalidated OOS result conclusively or inconclusively demonstrate causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide the rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but should not be limited to addressing the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequate scoping of each investigation and its CAPA\u003Cbr>o Revised OOS investigation procedures with these and other remediations\u003C\u002Fli>\u003Cli>A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include but should not be limited to significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure that all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Lack of adequate Quality Unit oversight\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your Quality Unit (QU) failed to exercise adequate oversight over your contract testing operations. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of restricted access and appropriate controls on computerized systems to prevent any potential alteration or deletion of laboratory data.\u003C\u002Fli>\u003Cli>Implementation of an effective document control system for issuance, tracking, and reconciliation of CGMP documents used for laboratory testing and analysis.\u003C\u002Fli>\u003Cli>Review and approval of an uncontrolled document, “Sample Prep Tips and Tricks,” used by laboratory staff for preparation of analytical samples.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response you state that moving forward, you will create individual logins on your computers, and you are looking into installing technology with audit trail capability. Further, you state that you will create templates for your forms and bind them into a book. You also commit to placing the unapproved sample preparation document, “Sample Prep Tips and Tricks,” into your controlled document system.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not include a comprehensive assessment into the vulnerabilities in your computerized systems that may have affected data integrity, nor do you explain how binding the templates into a book will remedy the deficiencies in your documentation control practices. Your response does not indicate whether your sample preparation protocols have been validated, to ensure that sample preparation is consistent and suitable for analysis. Finally, your response lacks details on how your QU will oversee CAPA implementation and evaluate their effectiveness.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure that your QU is given the authority and resources to function effectively. The assessment should also include but should not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations, to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU makes a decision concerning its disposition.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities and provides appropriate remediations for each of your laboratory and manufacturing computer systems. This should include but should not be limited to:\u003Cbr>Compounder’s International Analytical Laboratory, Castle Rock 3012069146 page 5\u003Cbr>o A list of all hardware that includes all equipment, both stand-alone and network, in your laboratory.\u003Cbr>o A list of all software configurations (both equipment software and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and versions, details concerning all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, with their organizational affiliation and title. Also describe how you will ensure that staff are not given administrative rights or other permissions that may compromise data retention or reliability.\u003Cbr>o System security provisions, including but not limited to whether unique usernames\u002Fpasswords are always used and their confidentiality is safeguarded.\u003Cbr>o Detailed procedures for robust use and review of audit trail data, and the current status of audit trail implementation for each of your systems.\u003Cbr>o Technological improvements to increase the integration of data generated through electronic systems from stand-alone equipment (for example, balances, pH meters, water-content testing equipment) into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> network.\u003Cbr>o A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, and to ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\u003C\u002Fli>\u003Cli>A comprehensive evaluation of your document “Sample Prep Tips and Tricks” and how it is used to determine the preparation method for analytical samples. Describe how you verify the suitability of the sample preparation method, and if you document the method in a sample preparation protocol that is reviewed and approved by the QU.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. In addition to the lack of effective management oversight of your laboratory operations, we found that your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>See FDA’s guidance for industry \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help in implementing an adequate Quality Unit (QU) in your laboratory operations to meet the requirements of CGMP.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responsibilities of a Contract Testing Lab\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients. It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any OOS results or significant problems encountered during the testing of these drugs.\u003C\u002Fp>\u003Cp>We also have concerns about the validity and integrity of the data you provided to outsourcing facilities registered under section 503B of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Testing Ceased\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the FDA inspection, you communicated your intention to shut down your contract testing laboratory and to cease operations. However, several statements made in your responses to the FDA Form 483 observations conflict with this declaration.\u003C\u002Fp>\u003Cp>In response to this letter, clarify the current operational status of your contract testing laboratory. If you plan to sell your laboratory, provide the name and address of the acquiring party.\u003C\u002Fp>\u003Cp>If you plan to resume contract laboratory testing operations regulated under the FD&amp;C Act, notify this office before resuming your drug testing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure that your firm can comply with ongoing CGMP. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>Note that remediating these CGMP violations will be necessary if Compounder’s International Analytical Laboratory, a successor, or an acquirer resumes drug testing operations at this site.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>If your firm intends to resume testing drugs for the U.S. market, you should engage a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations and deviations cited in this letter are not intended to be an all-inclusive list of violations and deviations that exist at your facility. You are responsible for investigating and determining the causes of any violations and deviations and for preventing their recurrence or the occurrence of other violations and deviations.\u003C\u002Fp>\u003Cp>Correct any violations and deviations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations and deviations may also prevent other federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations and deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations and deviations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration while we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012069146 and address it “ATTN: Christopher Keating.”\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Johnetta Walters, Ph.D.\u003Cbr>Acting Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>Cc:&nbsp;\u003C\u002Fp>\u003Cp>Nancy G. Sutton\u003Cbr>Vice President &amp; Owner\u003Cbr>Email: nsutton@compounderslab.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-101\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Ronald E. Sutton\n\nRecipient Title\n\nPresident & Owner\n\nChromatography Institute of America dba Compounder’s International Analytical Laboratory\n\n4760 Castleton Way, Suite A\n\nCastle Rock, CO 80109\n\nUnited States\n\nrsutton@compounderslab.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWarning Letter 320-25-101\nAugust 20, 2025\nDear Mr. Sutton:\nThe United States Food and Drug Administration (FDA) inspected your contract testing laboratory, Chromatography Institute of America dba Compounder’s International Analytical Laboratory, FEI 3012069146, at 4760 Castleton Way, Suite A, Castle Rock, Colorado, from February 24 to March 5, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) requirements for finished pharmaceuticals and significant deviations from CGMP for active pharmaceutical ingredients (APIs).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drugs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your March 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations and deviations including but not limited to the following:\n1. Lack of adequate laboratory control mechanisms\nYour firm conducts chemical and microbiological testing of APIs, drug products compounded by outsourcing facilities registered under section 503B of the FD&C Act, and finished drug products for human and animal use. Records and information collected during the inspection demonstrate that you use the same methods and procedures whether you are testing APIs, drug products compounded by outsourcing facilities registered under section 503B of the FD&C Act, or finished drug products for human and animal use.\nYou lacked adequate controls to ensure the reliability of your microbiological testing results. For example, you documented sterility failures for several samples prepared in a (b)(4) media lot, but you were unable to show that you performed growth promotion testing on this lot before use. In your investigations into these sterility failures, you noted “false positives” with this lot, but you did not include appropriate negative controls corresponding to this lot in your tests and lacked sufficient evidence to support your “false positives” statement. Moreover, after obtaining a failing sterility test result, you repeated the test on a fraction of the original sample amount, which is not in accordance with USP \u003C71> and is an unacceptable practice.\nIn your response, you state that you rely on your manufacturer’s certificates of analysis to establish media suitability. You indicate that you perform growth promotion testing (b)(4) and that moving forward, you commit to performing growth promotion testing on (b)(4) media lot. Additionally, you assert that you will revise your procedures to note that you will perform retesting of a failed sample, provided that sufficient sample quantity remains after initial testing. You also assert that you follow all aspects of USP \u003C71> “as best as is possible.”\nYour response is inadequate because you did not include a comparability analysis of your sterility test method and USP \u003C71> method, to show that your method is equivalent despite the deviations from USP \u003C71> requirements, such as growth promotion testing, negative controls, and sterility retest sample amounts. You also did not include any documentary evidence to support your assertions about random testing and updated procedures.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to evaluate and remediate the effectiveness of your laboratory system.\nA comprehensive assessment and remediation plan for your sterility testing procedure to ensure that it satisfies all requirements specified in USP \u003C71>. Include:\no Instructions for how you determine which of your method kits ((b)(4)) purchased from third-party suppliers are suitable for sterility testing of your laboratory samples.\no A requirement that each media lot used in the preparation of sterility samples on a given day will include an appropriate negative control.\no Requirements for appropriate sample amounts needed for a sterility retest.\nA remediation plan for qualification of your suppliers of growth media. Include a commitment to perform growth promotion testing on all incoming media lots used for microbial and sterility testing, to verify their suitability for use.\n2. Lack of adequate investigations\nYour investigations into multiple failed sterility test results were inadequate. In 2024, you had nine drug product sterility test failures, for which your investigation concluded that the probable root cause was “technician error – environmental contamination.” However, your root cause was not supported by the environmental monitoring data on the dates when the failing sterility samples were prepared. You did not recover any microorganisms on settle plates from your ISO 7 sterility suite, on ISO 5 “compounding aseptic isolators” where your sterility samples are prepared, or on contact plates used for monitoring of personnel who prepared the sterility samples. You subsequently performed a new analysis on the drug product samples, and you recorded the passing results.\nIn your response, you indicate that you initiated corrective and preventive actions (CAPA), which included the retraining of technicians and their dismissal upon repeated infractions, review of your sterility procedures and cleaning agents, and the frequency of cleaning the sterility suite.\nYour response is inadequate. You initially identified the potential root cause “technician error – environmental contamination” in 2024, and you continued to note this root cause in several subsequent sterility out-of-specification (OOS) investigations, without identifying and implementing the appropriate CAPA from these investigations to prevent similar future errors.\nIn response to this letter, provide:\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products for the last three years from the initial date of inspection, and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and the evidence relating to the invalidated OOS result conclusively or inconclusively demonstrate causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide the rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but should not be limited to addressing the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequate scoping of each investigation and its CAPA\no Revised OOS investigation procedures with these and other remediations\nA comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include but should not be limited to significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure that all phases of investigations are appropriately conducted.\n3. Lack of adequate Quality Unit oversight\nYour Quality Unit (QU) failed to exercise adequate oversight over your contract testing operations. For example, your QU failed to ensure:\nEstablishment of restricted access and appropriate controls on computerized systems to prevent any potential alteration or deletion of laboratory data.\nImplementation of an effective document control system for issuance, tracking, and reconciliation of CGMP documents used for laboratory testing and analysis.\nReview and approval of an uncontrolled document, “Sample Prep Tips and Tricks,” used by laboratory staff for preparation of analytical samples.\nIn your response you state that moving forward, you will create individual logins on your computers, and you are looking into installing technology with audit trail capability. Further, you state that you will create templates for your forms and bind them into a book. You also commit to placing the unapproved sample preparation document, “Sample Prep Tips and Tricks,” into your controlled document system.\nYour response is inadequate because it does not include a comprehensive assessment into the vulnerabilities in your computerized systems that may have affected data integrity, nor do you explain how binding the templates into a book will remedy the deficiencies in your documentation control practices. Your response does not indicate whether your sample preparation protocols have been validated, to ensure that sample preparation is consistent and suitable for analysis. Finally, your response lacks details on how your QU will oversee CAPA implementation and evaluate their effectiveness.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure that your QU is given the authority and resources to function effectively. The assessment should also include but should not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations, to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU makes a decision concerning its disposition.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities and provides appropriate remediations for each of your laboratory and manufacturing computer systems. This should include but should not be limited to:\nCompounder’s International Analytical Laboratory, Castle Rock 3012069146 page 5\no A list of all hardware that includes all equipment, both stand-alone and network, in your laboratory.\no A list of all software configurations (both equipment software and (b)(4)) and versions, details concerning all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, with their organizational affiliation and title. Also describe how you will ensure that staff are not given administrative rights or other permissions that may compromise data retention or reliability.\no System security provisions, including but not limited to whether unique usernames\u002Fpasswords are always used and their confidentiality is safeguarded.\no Detailed procedures for robust use and review of audit trail data, and the current status of audit trail implementation for each of your systems.\no Technological improvements to increase the integration of data generated through electronic systems from stand-alone equipment (for example, balances, pH meters, water-content testing equipment) into the (b)(4) network.\no A detailed summary of your procedural updates and associated training, including but not limited to system security control to prevent unauthorized access, and to ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\nA comprehensive evaluation of your document “Sample Prep Tips and Tricks” and how it is used to determine the preparation method for analytical samples. Describe how you verify the suitability of the sample preparation method, and if you document the method in a sample preparation protocol that is reviewed and approved by the QU.\nIneffective Quality System\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. In addition to the lack of effective management oversight of your laboratory operations, we found that your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nSee FDA’s guidance for industry Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help in implementing an adequate Quality Unit (QU) in your laboratory operations to meet the requirements of CGMP.\nResponsibilities of a Contract Testing Lab\nFDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients. It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any OOS results or significant problems encountered during the testing of these drugs.\nWe also have concerns about the validity and integrity of the data you provided to outsourcing facilities registered under section 503B of the FD&C Act.\nDrug Testing Ceased\nDuring the FDA inspection, you communicated your intention to shut down your contract testing laboratory and to cease operations. However, several statements made in your responses to the FDA Form 483 observations conflict with this declaration.\nIn response to this letter, clarify the current operational status of your contract testing laboratory. If you plan to sell your laboratory, provide the name and address of the acquiring party.\nIf you plan to resume contract laboratory testing operations regulated under the FD&C Act, notify this office before resuming your drug testing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure that your firm can comply with ongoing CGMP. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nNote that remediating these CGMP violations will be necessary if Compounder’s International Analytical Laboratory, a successor, or an acquirer resumes drug testing operations at this site.\nCGMP Consultant Recommended\nIf your firm intends to resume testing drugs for the U.S. market, you should engage a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP.\nConclusion\nThe violations and deviations cited in this letter are not intended to be an all-inclusive list of violations and deviations that exist at your facility. You are responsible for investigating and determining the causes of any violations and deviations and for preventing their recurrence or the occurrence of other violations and deviations.\nCorrect any violations and deviations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations and deviations may also prevent other federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations and deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations and deviations.\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration while we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012069146 and address it “ATTN: Christopher Keating.”\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nJohnetta Walters, Ph.D.\nActing Director\nDivision of Drug Compliance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\nCc:\nNancy G. Sutton\nVice President & Owner\nEmail: nsutton@compounderslab.com","Chromatography Institute of America dba Compounder’s International Analytical Laboratory","chromatography-institute-america-dba-compounders-international-analytical-laboratory-708944-08202025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchromatography-institute-america-dba-compounders-international-analytical-laboratory-708944-08202025","2026-10-26T08:08:15.132992+00:00","2025-09-02","708944","Animal & VeterinaryDrugs","Mr. Ronald E. Sutton","2026-08-19T16:26:38.524+00:00","320-25-101","2025-08-20",12,{"510k":246,"classification":247,"enforcement":248,"event":249,"event_backfill":250,"pma":251,"warning_letter":252},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-19T04:00:36.695+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]